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ABSTRACT
Multi-Processor Computation of Thrombus Growth and Embolization
in a Model of Blood-Biomaterial Interaction
Based on Fluid Dynamics
Brandon Andersen
Department of Chemical Engineering, BYU
Master of Science
This work describes the development and testing of a real-time three-dimensional
computational fluid dynamics simulation of thrombosis and embolization to be used in the
design of blood-contacting devices. Features of the model include the adhesion and aggregation
of blood platelets on device material surfaces, shear and chemical activation of blood platelets,
and embolization of platelet aggregates due to shear forces. As thrombus develops, blood is
diverted from its regular flow field. If shear forces on a thrombus are sufficient to overcome the
strength of adhesion, the thrombus is dislodged from the wall. Development of the model
included preparing thrombosis and embolization routines to run in a parallel processing
configuration, and estimating necessary parameters for the model including the adhesion strength
of platelet conglomerations to the device surfaces and the criterion threshold for the coalescence
of neighboring thrombi. Validation of the model shows that the effect of variations in geometry
may be accurately predicted through computational simulation. This work is based on previous
work by Paul Goodman, Daniel Lattin, Jeff Ashton, and Denzel Frost.

Keywords: Brandon Andersen, thrombosis, embolization, computational fluid dynamics,
simulation, parallel processing, shear and chemical mediated platelet activation
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1

INTRODUCTION

Since  the  1980’s,  blood-contacting devices, including artificial hearts, catheters, grafts,
heart valves, and stents, have made up a large portion of the medical device industry[1]. These
devices are largely responsible for dramatic improvements in cardiovascular-related mortality
including, for example, a 40% decrease in heart attack mortality from 1980 to 2000[2]. The
benefits of blood-contacting devices are clear, however their use is not without risk. Thrombosis,
the growth of blood aggregates on biomaterial surfaces, and thromboembolism, the subsequent
embolization of those blood aggregates, have been documented in blood-contacting devices as
early as 1959[3-5] and are a major cause of death for cardiovascular device patients. Despite
more than a half century of intense research, the principles of the physical and chemical design
of materials and devices that control the blood-material interactions which result in
thromboembolic events are not fully understood[6].
“Virchow’s  Triad”  identified  blood,  surface,  and  flow  as  the  three  factors  that  govern  
thrombosis and embolization over 100 years ago[7]. Since that time, and especially in the last 30
years, since the advent of the cardiovascular stent, researchers have sought to better understand
the mechanisms of thrombosis. Research has identified many key blood chemicals and
components  and  their  role  in  thrombosis;;  comparatively  “bioinert”  materials,  appropriate  for  use  
in the body, have been identified through experimentation; and the advances in Computational
Fluid Dynamics (CFD) have enabled a much more thorough understanding of the flow of blood
through and around devices. However, because of the complexity of, and interaction between,
1

these factors[8, 9], the development of a comprehensive three-dimensional transient
computational model of the formation, growth, and embolization of thrombi associated with
cardiovascular devices has proven difficult. Such a computational model would be invaluable in
the successful design of devices that minimize the threat of thromboembolic events.
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2.1

BACKGROUND

Thrombosis and Embolization
The events of thrombogenesis can be grouped into the following three categories: 1)

protein activation and adsorption, 2) platelet and leukocyte activation and attachment, and 3)
thrombus growth and detachment[10, 11]. This categorization of events permits the systematic
examination of the processes known to contribute to thrombosis and thromboembolism.
All materials exposed to blood adsorb within seconds a thin layer of proteins[12], mostly
fibrinogen[6]. Multilayers of protein continue to build on the initial monolayer of proteins. In the
absence of anticoagulants, contact with the surface causes proteins to adhere, and in the case of
complement and coagulation proteins, activates the proteins and initiates a cascade of reactions
that result in the creation of thrombin and fibrin, which in turn activate more proteins, and blood
platelets, forming a mesh for the conglomeration of those proteins and platelets[11].
Chemical agonists, such as adenosine diphosphate (ADP)[13], and shear forces[14]
activate platelets in the blood stream and previously unactivated adherent platelets. Activated
platelets become sticky[15], deform to irregular spheres with spiny pseudopods[16], and release
agonists[13], which activate neighboring platelets. The activated platelets (as well as unactivated
platelets) carried to the wall by diffusion and convection adhere easily to protein molecules and
other activated platelets on a material surface[17]. Leukocytes, or white blood cells, and
complement proteins are believed to contribute to thrombosis[11], however their relative
importance in the mechanisms of thrombosis and thromboembolism is not known[18].
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Thrombosis proceeds through the reaction cascade initiated by the activated proteins, and
relies on the continued transport of proteins and platelets to the surface of the forming thrombus.
As the thrombus grows, it disrupts the flow patterns of the surrounding blood, which causes
increased flux of proteins and platelets to the surface, as well as increased shear rates. As the
thrombus continues to grow into the flow path, the shear stress may overcome the adhesion
strength of the thrombus to the surface, causing it to break off of the material surface and enter
the flow stream[19]. Over time, the fibrin may break down or the monolayer proteins may be
denatured, also resulting in a release from the wall[10, 20].

2.2

Computational Models of Thrombosis and Embolization
Many models have been developed which attempt to describe thrombosis and/or

thromboembolization. While most aspects of the processes have been modeled in some way,
most models focus on a single component rather than the process as a whole, and are devised in
such a way that precludes their extension to transient flow through a three-dimensional
geometry.

2.2.1 Platelet Adhesion
In 1972 Peter D. Richardson[21] was the first person, known to the author, to model
thrombosis. His model, which focused only on platelet activation by chemical agonists, consisted
of platelets in steady concentration flowing in a linear velocity profile next to a wall. A
maximum thrombus  radius  was  assumed  and  used  to  define  a  “concentration  layer”  of  agonist  
around a pre-existent seed thrombus. The agonist concentration layer was assumed sufficient to
activate any platelet that entered it after a characteristic time. If an activated platelet remained in
the immediate vicinity of the thrombus (defined by the agonist concentration layer) when
4

activation time was reached, it was added to the thrombus volume. The model, although
primitive, was consistent with the data collected two years earlier by Begent and Born[22],
which suggested that the growth rate was exponential in time and was zero above some critical
velocity.  Richardson  called  his  work,  “a  simplified  model  that  predicts  observed  behavior.”[21]
In 1977, Ruckenstein et al.[23] added a kinetic expression for the adhesion of platelets to the
thrombus mass which produced a plateau in thrombus growth rate, consistent with experimental
observation[24].

2.2.2 Protein Adsorption
Many models of protein adsorption exist[25-30]. One of the most detailed of these
models was developed by Madrusov et al.[28]. It predicts in real time the competitive and
displacement adsorption of specific proteins. Because protein adsorption is a complicated
process, and only a small part of a comprehensive thrombosis model, the reader is referred to the
review of significant protein adsorption models by Madrusov et al.[28] for additional
information on this topic.

2.2.3 Comprehensive Models
Marmur and Cooper[31] combined protein adsorption and detachment to platelet
activation and deposition in their 1982 model, creating the first computational model that
incorporated protein and platelet adhesion as well as thrombus growth and embolization. The
model broke the process of thromboembolization into the following steps: (1) deposition of a
first layer of platelets directly on the bare surface, (2) multilayer deposition of platelets on the
first platelet layer, (3) adsorption of a first layer of protein directly on the bare surface, (4)
multilayer adsorption of protein onto the basal protein layer, (5) Deposition of a first layer of
5

platelets on a protein layer, (6) multilayer deposition of platelets on the first layer of platelets
deposited on a protein layer, and (7) protein desorption after a characteristic time representative
of protein denaturation (proteins desorbed were assumed to carry with them all of their protein
and platelet deposits). The expression for each for these steps included a kinetic parameter that
was fixed in order to be consistent with experimental observation of growth rate over time.
Equations were solved using the 4th-order Runga-Kutta method with an initial condition of no
protein or platelet surface coverage. Activation of proteins and platelets was not treated. This
model was later extended by Wilson et al.[32] in 1986 to include an eighth step: (8) embolization
of thrombi due to hemodynamic forces. The underlying principle of the mechanism was that
thrombi that attained a critical size were subject to forces that removed them from the surface.
This removal carried away everything deposited beneath the thrombi.
Marmur  and  Cooper’s  model,  with  Wilson  et  al.’s  extension,  was  important  in  that  it  was  
the first comprehensive model of thromboembolism; however it did not predict
thromboembolism in a way that could be applied to actual cardiovascular devices[33]. Surface
coverage of proteins and platelets was a controlling variable in the kinetic expressions used, as
would be expected in an adsorption model, however this variable was also used to define the
characteristic  size  and  height  of  a  thrombus  by  taking  an  average  height  of  “layers”  of  surface  
coverage. Because the size and shape of the thrombus was not well defined, an account of its
effect on local hemodynamics was not possible, nor was embolization due to realistic
hemodynamic forces.
Reynolds et al.[10] improved on the Wilson et al. model in 1993 by considering the
coexistence of three distinct proteins: platelet-adherent  proteins  (fibrinogen),  ‘other  proteins’  
(albumin), and active coagulation factors (Factor XII). The proteins functioned separately in that
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platelets were allowed  to  deposit  only  onto  ‘fibrinogen’  proteins,  and  Factor  XII  participated  in  
the thrombosis processes by producing fibrin and fibrin-related platelet-platelet bridges.

2.2.4 Computational Fluid Dynamics Models
In more recent years, Computational Fluid Dynamics (CFD) has become a central
component of many of the models developed to simulate thrombosis. Many groups are using
CFD in three-dimensional geometries at steady state in order to investigate shear stress and
stagnation time, which are good predictors of thrombosis and embolization[34-40].
Unfortunately these models only give a probability map of where thrombi are most likely to form
in the device without providing any kind of a prediction of their size, growth rate, or
embolization.
In several studies, models of protein and/or platelet functional behavior in addition to
two-dimensional CFD were used to predict thrombosis in various geometries[7, 33, 41].
Sorensen et al.[7] developed such a model incorporating platelet activation, agonist synthesis and
release by activated platelets, and thrombin generation and adhesion. The model required the
estimation of four parameters to fit it to experimental data: shear-dependent platelet diffusivity
and three platelet-deposition-related reaction rate constants. After determining values for the
model parameters for platelet deposition onto a collagen substrate by fitting to experimental data,
the model was validated by comparison to literature data for flow between parallel plates. The
model provided good predictions of deposition trends and magnitudes for data taken in the
presence of heparin, but not in the presence of citrate. The model, which was never extended to
three dimensions, also failed to include embolization of platelet aggregates. Goodman et al.[33]
developed a similar model, borrowing heavily from the reaction expressions and constants
compiled by Sorenson et al., but included both single platelet and platelet aggregate embolization
7

and alterations of local fluid dynamics due to the presence of a thrombus. His model was useful
in the prediction of initial or acute thrombosis, but was limited in the time duration of
simulations because it predicted that thrombus eventually formed on all surfaces in the model.
Daniel Lattin, Jeff Ashton, and Denzil Frost performed subsequent work to port Goodman's
model to a new commercial CFD package, STAR-CD® (CD-adapco, Melville, NY) which
allowed easier modeling of more complex medical devices by its auto-meshing tool and
extension  of  Goodman’s  model  to  three  dimensions,  and  improved  the  prediction  of  
thromboembolism due to shear forces. While they were successful in developing a working
model, several aspects of the model were not validated, and preliminary results suggested that
the code was not completely working as intended. Areas of concern in their model include the
following:
Parallel processing. The Goodman and Lattin-Ashton-Frost models were written without
attention to the complications of multi-processor parallel computing, a feature of supercomputers
that significantly reduces computation time. STAR-CD® uses the MIMD (Multiple Instruction
stream, Multiple Data stream) technique for parallel processing, which is the most common
parallel arrangement. In MIMD processing, one code is written and each processor runs the code
on independent data. In the case of an MIMD problem utilizing domain decomposition, each
processor runs the code for the fraction (domain) of the model assigned to that processor.
Domain decomposition is performed on the three-dimensional model space automatically by
STAR-CD®. Each requested processor is assigned an approximately equally sized subsection of
the total volume for which it solves the transport equations necessary to give the flow solution
and runs code predicting thrombosis and embolization. Also, the hardware of the BYU
supercomputer is set up to use distributed memory (each processor has its own memory), which
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is highly scalable but is also more difficult to program than a shared memory arrangement (in
which every processor has direct access to one global memory space). Complications arise with
the domain decomposition in our problem where we are not only solving for micro-scale 3dimensional flow, but also describing macro-scale growth of thrombi. Some thrombi will initiate
in one processor domain but will extend into the domain of another processor, which may require
that one processor has access to memory stored on other processors. Simulations by the LattinAshton-Frost model where such extension was not accommodated predicted the formation of
thrombi that were bounded by domain boundaries.
Volume discretization. The method for solving flow fields using computational fluid
dynamics involves discretizing the physical domain into 3-dimensional cells. The properties of
the fluid within each cell are assumed to be uniform, and the equation of motion is solved in
agreement with the equation of continuity in each cell. The justification of uniform conditions in
a cell requires that the cell be small enough to not encompass a large change in physical
properties, or velocity. The cells must also be small enough to estimate the derivative across a
cell with sufficient accuracy. Examination of the volume discretization used in the LattinAshton-Frost model reveals cells that are too large to ensure accuracy in these assumptions.
Flow around growing thrombi. Goodman’s  model  employed  with  success  a  method  of  
altering flow patterns to accommodate the growth of thrombus by increasing the viscosity of
cells designated as thrombus. Viscosity was increased from .0035

to 1

to stop fluid

flow within the cell and cause the surrounding fluid to flow around the thrombus cell. The
alteration of the flow field by the presence of thrombus is important to the simulation in the
calculation of growth rates and the shear force exerted on the thrombus, which may cause it to
embolize.
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Lattin,  Ashton,  and  Frost’s  version  of  the  model  in  STAR-CD® attempted to employ the
same method, however it has been found that for computational cells for which the viscosity was
reported to increase as desired, the flow field remained unaltered.
Input parameters. The predictions of the model are based upon a system of equations
involving 1) the rate of transport and adhesion of both resting and active platelets to the device
wall and existing thrombus, 2) the convective and diffusive transport and production and
consumption of chemicals involved in the activation of platelets, and 3) the activation of platelets
due to both shear forces and chemical agonists. While all of these processes are included in the
model presented by Goodman and later by Lattin, Ashton, and Frost, large discrepancies exist
between model predictions and observed behavior. The model predicts thrombosis in locations
and formations that differ from experimental observations, and the predicted rate of thrombosis
is many times too fast. These results suggest that a careful critical review of calculations and
input parameters should be performed.
In addition to a critical review of the computational code governing the processes of
thrombosis and embolization, two key parameters must be estimated. The model requires values
for the strength of adhesion of a mass of platelets to the wall of a blood-contacting device
(measured in N/m2) and requires a criterion for the coalescence of neighboring thrombi.
Experimental observation suggests that as two thrombi grow in the same region, they may
become infused to the point that they will no longer embolize and separate thrombi, but as a
single mass. In our code the criteria for this coalescence effect is that a specific threshold percent
of total surface area of a thrombus be in contact with an adjoining thrombus. The estimation of
these two parameters is essential to achieving accurate results from the simulation.
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Runtime efficiency. Lattin, Ashton, and Frost made significant progress toward
developing a code that described the growth and embolization of thrombi, but were not able to
address the issue of run time efficiency. Ten minutes of simulation time using their model in
STAR-CD® typically required up to a week running on the BYU supercomputer, but that time
likely could be reduced by judicious optimization of the code. Areas of concern have been
identified to improve the runtime efficiency. These include 1) removing redundant and
unnecessary calculations and data storage, 2) using a volume mesh density that assures grid
independence without requiring excessive runtime, and 3) setting the residual tolerance for the
convergence process to achieve adequate precision without undue iteration.
Calculation tracking. An obstacle to finding errors in the model is that the standard
methods of presenting results in Star-CD are limited to a series of plots of the transient solution
of variables such as thrombus presence and fluid velocity. Running the model on the
supercomputer (which is necessary at this point) does not allow a user to step through the
calculations and verify that the model is functioning as designed. Tools need to be developed
within the user code to follow all the calculations and progression of thrombosis in a single cell
or of a single thrombus in the model to help identify the causes of existing errors and their
solutions  and  ultimately  to  increase  confidence  in  the  model’s  predictions. These same tools will
allow the user to collect data on thrombus growth and embolism events which STAR-CD® does
not natively provide.

2.2.5 Other Models
Aaron Fogelson has been building a model of platelet interaction with a damaged vessel
wall in connection with several researchers including Robert Guy[42] and K. Leiderman[43].
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These models take the unique approach of tracking every individual platelet. While
computationally  expensive,  Fogelson’s  model  incorporates  the  activation  of  platelets,  adhesion  to
a damaged endothelial wall and to other activated platelets, thrombus growth and effect on flow
patterns, and embolization by shear forces all in real time in 2-dimensional space. The model
provides good prediction of thrombosis growth and embolization trends. Predicting thrombosis
locations  in  a  medical  device  with  Fogelson’s  model  would  require  expansion  to  three  
dimensions and much larger systems and altering parameters to reflect the difference between a
damaged endothelial cell wall and an artificial material surface, which would make the
computational solution far too costly for practical use.
Other methods used in the modeling of platelet thrombosis include a multi-scale model
by Xu et al.[44] and a particle dynamics model by Filipovic et al.[45]. These models focus on
venous thrombus formation through the intrinsic reaction cascade, and arterial thrombus
formation through platelet activation and adhesion, respectively. Neither model endeavors to
predict thrombosis and embolization occurring in real time.

2.3

Experimental Studies of Thrombosis
Any computational model to be used in predicting thrombosis and embolization must be

validated  by  comparison  to  experimental  observation.  Goodman’s  model  was  no  exception.  In
connection with his computational model, Goodman designed and performed experiments to
observe the processes of thrombosis and thromboembolization[33]:
Human blood was drawn into heparin (final concentration

) from donors free

of platelet-affecting drugs and was perfused through cylindrical flow cells at 0.75
flow cells (see Figure 2-1) were constructed from 580-
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. The

ID Polyethylene (PE) tubing into

which smaller-diameter tubing segments (also PE, 280-

ID) had been inserted to produce

abrupt contractions and expansions in the flow path.

Figure 2-1 Experimental flow cell

Thrombus initiation, growth, and embolization were observed with videomicroscopy,
while embolization was confirmed by light scattering, and platelet adhesion was determined by
scanning electron microscopy. Thrombus growth rate was recorded as the change in thrombus
height (distance from surface to furthest point of thrombus) over time. Thrombus was observed
in three key areas: Area 1) the sudden contraction, Area 2) the sudden expansion, and Area 3) the
reconnection point after the sudden expansion. The constricted flow section contained a lack of
adhered platelets.
Whereas most thrombosis experiments focus on the state of thrombus after a set growth
period,  Goodman’s  model  is  unique  in  providing  real-time monitoring of both thrombosis and
embolization. This makes it easily comparable to the results of a computational model, which
also provides real-time growth and embolization patterns.
Corbett et al.[34] performed similar experiments involving blood flow through a step
change.  Corbett’s  experimental  setup  consisted  of  bovine  blood  heparinized  at  a  concentration  of  
3

heparin in a flow loop. Thrombus size and location were recorded after 2 hours of flow.

Data on growth rate and embolization was not recorded. A digital replica of the experiment was
used to compare the thrombus sites to wall shear rates. It was determined that thrombus initiates
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at wall shear rates below 54

, differing from the threshold of 10-20

as reported in Corbett

et  al.’s  literature  search [46-49]. Corbett concluded that the discrepancy might be due to the
altered flow field produced by the presence of thrombi.
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3

OBJECTIVES

Goodman, Lattin, Ashton, and Frost put much of the framework in place for an accurate
model of blood material thrombosis and embolization; however, errors and inconsistencies
prevented the model from being a reliable tool in the design of cardiovascular devices. The goal
of this work was to  create,  from  Goodman,  Lattin,  Ashton,  and  Frost’s  previous  work,  a  reliable  
predictive model of thrombosis and embolization to be used as a tool in cardiovascular device
design. This was accomplished by completion of the following objectives:

1.

Constructing the Model
a. Parallelize the thrombosis and embolization code.
b. Correct the code to successfully simulate the flow of blood around each
thrombus.
c. Perform detailed tracking of targeted cells to verify the correct functioning of
the code.
d. Optimize the code to minimize runtime by 1) removing redundant and
unnecessary calculations and data storage, 2) determining an optimum mesh
density, and 3) determining an optimum residual tolerance for the
convergence process.
e. Select a magnitude of the contact area criterion for coalescence of neighboring
thrombi, and select a magnitude of the platelet adhesion strength.
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2.

Demonstrate   the   model’s   ability   to   compare   flow   geometries by predicting the
effect of insert spacing in the flow cell.
The present model is intended to independently predict the effects of device
design on thrombosis and embolization. To demonstrate the predictive nature of
the  model,  variations  on  Goodman’s  original flow cell will be constructed with a
range of insert spacing (see Figure 5-1). The effect of the variations will be
studied in both the experimental setup and the computational model.

3.

Demonstrate  the  model’s  use  for  designing  a  hemodialysis  catheter.
Thrombosis and embolization will be simulated in a model of a standard
Mahurkar blood catheter and in a Mahurkar blood catheter that has been modified
in a way that is expected to decrease thrombosis and embolization The Mahurkar
blood catheter standard design includes eyelet perforations where entering blood
is directed perpendicular to the catheter wall and the direction of bulk flow. It is
believed that altering the angle of flow will decrease shear activation and
thrombosis in the catheter.

The completed model can potentially be a powerful tool in the development of bloodcontacting devices that limit the risk of thrombosis and thromboembolization. Model predictions
include total thrombus mass over time, thrombus growth locations and relative rates, and
embolization size and frequency. Common modeling software packages like AutoCAD®
(Autodesk, San Rafael, CA) and SolidWorks® (Dassault Systèmes SolidWorks Corporation,
Waltham, MA) can produce model geometries which may then be used by STAR-CD® in
conjunction with the specialized thrombosis and embolization code described in this work to
evaluate any device design and its risk of thromboembolic events.
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4

CONSTRUCTING THE MODEL

The Lattin-Ashton-Frost model is a computational fluid dynamics simulation performed
by STAR-CD®’s  Pro-STAR solver using the SIMPLE algorithm for transient simulation.
Transport and conservation equations are solved for unactivated platelets, activated platelets,
adenosine diphosphate (ADP), thromboxane A2 (TxA2), prothrombin (pT), thrombin (T), and
anithrombin III (aT). Source terms include boundary reactions, chemical synthesis and
consumption reactions, and platelet activation due to both shear effects and chemical activation.

Table 4-1 Processes in computational cells and defined thrombus
Level
Order
Computational Processes
1

Platelets (resting and active) transport and
adhere to the device surface or existing
thrombus as governed by rate equations

2

Incoming platelets cause the fraction of the
cell's volume occupied by thrombus
(ThrFr) to increase over time

3

When ThrFr reaches 1.0, the cell is defined
as a thrombus cell and fluid is diverted
around it

4

Neighboring cells are identified and
allowed to continue the growth of the
thrombus

5

The thrombus is evaluated against the
coalescence criteria

6

The thrombus is evaluated against the
embolization criteria

Cell

Thrombus
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The simulation functions on two levels: 1) the computational cell, and 2) the thrombus.
The processes that take place in each category are tabulated in Table 4-1.
While the Lattin-Ashton-Frost model provided a good foundation for this work, there
were many improvements that needed to be made in order to prepare the simulation for use in the
design of blood-contacting devices. These improvements included parallelizing the thrombosis
and embolization code, directing flow around growing thrombi, implementing calculation
tracking, cleaning up thrombosis and embolization algorithms, and estimating necessary
parameters. These improvements are summarized in Table 4-2.

Table 4-2 Summary of Model Improvements
Improvement
Result
Redesigned and
Allows for growth of
User subroutines written
implemented subroutine
thrombi across processor
for a single processor
algorithms for parallel
boundaries and valid
processing
multiprocessor computing
Thrombus growth into the
Increased the viscosity of
Thrombus did not
flow volume redirects flow
thrombus sufficiently to
redirect flow
creating variation in shear
preclude flow
rates and residence time
Error diagnostic identified
mistakes in user
Undiagnosed errors
A tracking and error
subroutines
prevented successful
diagnostic routine was
Tracking provides
completion of simulation written and included in
validation of successful
run
the code
completion of all
subroutines
Subroutines were
Code inefficiencies
redesigned to avoid
greatly extended
Reduces runtime by 50%
unnecessary loops,
runtimes
calculations, and storage
Values for platelet
Necessary model
Model predictions for
adhesion strength and
parameters were
embolization events match
thrombus coalescence
estimated by statistical
experimental results for the
contact area threshold
optimization to fit
same conditions
were unknown
experimental results
Previous
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4.1

Parallelize the Thrombosis and Embolization Code
The simulation of thrombosis and embolization is possible through user subroutines that

handle the mechanics of platelet adhesion and embolization rates as well as criteria for
thromboembolization. These subroutines were written by Goodman for the original FLUENT®
(ANSYS, Canonsburg, PA) model, then later adapted to STAR-CD® and improved by Ashton,
Lattin, and Frost. The STAR-CD® model took advantage  of  Brigham  Young  University’s  super  
computer in order to run on parallel processors and significantly decrease runtime. However, the
authors of the model did not take into account how parallel processing might affect the
subroutines.
Parallel processing in STAR-CD® uses automatic domain decomposition to divide
computations evenly between available processors. Each processor is assigned an approximately
equal portion of the flow volume for which it will solve the necessary transport equations for the
entire simulation. Figure 4-1 shows the domain boundaries in a 64-processor simulation.

Figure 4-1 Flow cell geometry showing typical processor-domain boundaries for 64 processors

Solver algorithms ensure that transport equation solutions are consistent across all
processors. This works very well for the transport equations which STAR-CD® is designed to
solve. However, domain decomposition makes the prediction of thrombosis and embolization,
which often requires that information local to a thrombus, more difficult. In many instances a
thrombus may reside on or near a processor boundary, which will prevent the code from
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gathering the necessary information about local conditions that affect thrombus growth. The
thrombosis and embolization code must be written to include multi-processor communication in
order to accommodate the growth, coalescence, and embolization of thrombi across processor
domains.
The result of running the original code on multiple processors was that all thrombi were
unintentionally restricted to the processor domain in which they were initiated, resulting in
unrealistic growth patterns. To accommodate the growth, coalescence, and embolization of
thrombi across processor domains, Message Passing Interface (MPI) like instructions specific to
STAR-CD® were utilized. These allow for information sharing between processors at strategic
points in the code, as well as calculation, storage, and communication of necessary information
in a manner that ensures correct and consistent data storage across all processors.
The algorithm of the thrombosis and embolization routine both with and without the MPI
implementation is outlined in the flowcharts in Figure 4-2. Sharing information across processors
at the key locations indicated in the flowchart allows thrombus to grow across processor domain
boundaries. An example of these multi-processor thrombi can be seen in Figure 4-3.
Besides  the  “share  info  between  processors”  procedures  which  were  added  to  the  routine,  
it was also necessary to store a global thrombus array on all processors that could store the sum
of all necessary information gathered about a thrombus from all the processors in whose domain
it exists. For example, a thrombus which bridges two processor domain boundaries will have
values from each of the three processors in which it is found indicating the size of the thrombus,
shear force pulling on the thrombus, adhesion strength of the thrombus to the wall, and surface
areas against neighboring thrombi. To accurately discover if the thrombus meets the criteria for
coalescence with a neighboring thrombi or embolization from the wall, the information from all
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processors must be systematically totaled and stored at every time step so that every processor
will reach the same conclusion when evaluating the thrombus against coalescence and
embolization criteria.

Figure 4-2 Flowchart representing thrombosis and embolization routine algorithm with (right) and
without (left) MPI implementation for parallel processing

Figure 4-3 Example of successful growth of thrombi (shown in red) across processor domain
boundaries
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4.2

Simulate the Flow of Blood Around Thrombi
Many researchers have tried to predict thrombosis in blood-contacting devices based on

the flow dynamics within the device. The problem with that method is that the event that is
predicted – thrombosis – will strongly affect the conditions upon which the prediction is made –
the flow field inside the device. One of the key features of this model is that as a thrombus grows
into the flow field, the flow field is altered to reflect the disturbance. Flow conditions that may
have originally precluded thrombus formation may now encourage it because of upstream or
downstream disturbances.
The flow disturbance is created in the model by dramatically increasing the viscosity of
the blood in thrombus regions. The highly viscous regions cause blood to flow around them as
do physical thrombi. The flow disturbance creates areas of both stagnation and increased flow
velocity and shear force. The change of a thrombus region from the constant viscosity of blood
(0.0035

) to a viscosity sufficiently high to stop flow (1.0

was used) is made

gradually to more accurately represent the process of thrombus formation and avoid a diverging
solution from the solver. (Note that it was not necessary to determine the actual viscosity of a
formed thrombus, only to set the viscosity of the thrombus in the model to some value
sufficiently high to divert flow.)
Lattin,  Ashton,  and  Frost’s  version  of  the  model  in  STAR-CD® attempted to employ the
same method; however, it was not accomplished successfully due to errors in the thrombosis and
embolization subroutines. The result was a slight increase in molecular viscosity, but not enough
to completely stop flow in the thrombus region. This can be seen in Figure 4-4.
These figures were taken from a simulation using the Lattin-Ashton-Frost model (note
that at the time their model was used the authors employed a much courser volume mesh, which
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is why the figures look very rough). Figure 4-4(a) shows thrombus growth after 102 seconds of
simulation time. A thrombus, which extends into the flow field, has formed at the first sudden
contraction point. If the model worked correctly, the thrombus would stop the flow and all fluid
flow would be diverted around the growing thrombus. Figure 4-4(b) shows the velocity profile at
the same moment as is seen in Figure 4-4(a). The velocity profile shows some disturbance of the
flow in the thrombus region, but not a complete stop. The viscosity of the thrombus regions was
being raised, but the jump only represented 10% of the desired viscosity change.
Correctly altering the thrombus viscosity was a key to obtaining accurate predictions
from the model. Finding and correcting the error allowed us to raise the viscosity to the desired
level and completely stop flow in the thrombus region. Figure 4-5 shows flow diverted around
the growing thrombus at the sudden contraction point.

Figure 4-4 (a) Predicted thrombosis and (b) velocity profile (m/s) from the Lattin-Ashton-Frost
model
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Figure 4-5 Velocity profile (m/s) (a) before and (b) after thrombus growth (thrombus indicated by
white region in figure b)

4.3

Perform Detailed Tracking of Targeted Cells and Thrombi
Early in the evaluation of the Lattin-Ashton-Frost code, the simulation showed errors in

thrombus growth patterns. It was easy to insert diagnostic routines to check for errors, but it was
more difficult to discover the source of the error. To allow for more transparency in the
execution of the model and the development of thrombi in the device, an option for executing the
code with progression tracking was added. This addition performs detailed tracking of any
targeted cell or thrombus and reports, at time of execution, all computational steps shown in
Table 4-1 including the correct evaluation of all computational expressions, and storage and
recall of values to and from the STAR-CD® solver. In the case of cells or thrombi that exist on
the boundary between processors, the tracking code executes on multiple processors giving the
development history as seen from all processors with information on the cell or thrombus
designated. Diagnostic tools were also designed and implemented to identify and report errors
periodically in the code. These improvements helped identify the problem of running the code on
multiple processors before changing the subroutines for parallel processing and were especially
useful in ensuring the accuracy of thrombus coalescence and embolization that occurs across
multiple processors.
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4.4

Optimize the Code to Minimize Runtime
Removing redundant and unnecessary calculations and data storage. Initial

development of a code is often more focused on utility than efficiency. As a result, a careful
review of code algorithms revealed many opportunities for runtime efficiency improvements.
Figure 4-6 shows major changes made to the coalescence and embolization routine.

Figure 4-6 Coalescence and embolization routine (a) before and (b) after optimization
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The changes include only looping through relevant thrombi for calculations (either
current thrombi for outer loop, or neighboring thrombi for inner coalescence loop), and avoiding
the embolization routine entirely for thrombi that have coalesced with a neighboring thrombus.
These changes and others like them resulted in an approximately 50% reduction in overall
runtime.
Determining an optimum mesh density. The method for solving flow fields using
computational fluid dynamics involves dividing the physical domain into discrete threedimensional cells. The properties of the fluid within each cell are assumed to be uniform, and the
equation of motion is solved in agreement with the equation of continuity in each cell.
Justification for the assumption of uniform conditions in a cell requires that the cell be small
enough to not encompass a large change in physical properties, or velocity. The meshing
guidelines established for the Lattin, Ashton, and Frost model result in cells that are too large for
accurate computation (see Figure 4-7).

Figure 4-7 Cell stencil from Lattin-Ashton-Frost model
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A series of simulations were run over a range of cell densities (

) to

determine the necessary grid resolution for grid-independent solutions. Figure 4-8 shows that cell
densities below 2 resulted in larger average embolus volumes. To distinguish between cell
densities greater than or equal to 2, thrombus locations were examined.
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Figure 4-8 Average embolus volume vs. cell density

Figure 4-9 Thrombus location map
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6

Figure 4-9 shows that the cell densities of 2 and lower have significantly more thrombus
in the flow cell. Cell densities greater than 2 are all very similar in terms of the occurrence of
thrombus over time. Variations exist in the appearance of thrombus in the outlet region, but the
randomness of their appearance confirms that this is not the result of a specific range of cell
density.
The optimal cell density will have cells small enough to justify the assumption of intracell uniformity but no smaller in order to optimize computation time. After examining the results
of the cell density study, a cell density of 2.5 was chosen as the standard. Figure 4-10 shows that
the new standard cell density is significantly finer in nature than the previously suggested mesh
(Figure 4-7).

Figure 4-10 Established standard cell stencil (2.5×1015 cells/m3)

Determining an optimum residual tolerance for the convergence process. Optimizing
the residual tolerance of a CFD model is important not only for speed of solution, but also for
accuracy. The goal of optimizing the residual tolerance is to find the highest residual tolerance
that achieves an accurate solution. To determine the optimum residual tolerance, tolerances of
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0.008, 0.03, and 0.05 were used in otherwise duplicate simulations and the results compared (see
Figure 4-11). This range was chosen based on the suggested tolerance for transient simulations
using the SIMPLE solver method of 0.05 and the achievable tolerance in less than 100 iterations
of approximately 0.008.
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Figure 4-11 Average embolus volume vs. residual tolerance

Results show no advantage to tightening the residual tolerance to 0.008 and therefore
0.05 represents the tolerance with the highest runtime efficiency and achievable accuracy.

4.5

Estimate Necessary Model Parameters
The thrombosis and embolization routine requires the use of two unknown values: the

area criterion for coalescence of neighboring thrombi and the platelet adhesion strength.
Statistical methods were used to estimate these parameters by exploring the influence of
variations in the coalescence criterion and adhesion strength on embolus size and number of
emboli and comparing the response surface to actual experimental results. A central composite
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design with additional points (at the standard distance of

from the center) to measure

curvature was used to create the response surface.
The adhesion strength was estimated by Goodman[33] to be around 10

.

Experience with the present model suggested that a slightly lower value would result in
embolization patterns more consistent with experimental results. For this reason, 8
used as the center point for the adhesion strength variable. A range of 5
chosen because  it  would  include  Goodman’s  original  estimate  of  10  

was

to 11

was

.

The coalescence criterion used in the model is that a minimum threshold of percent of
total surface area of a thrombus be in contact with another thrombus. If the threshold is reached
or exceeded, the two thrombi coalesce. The greatest contact area percent possible with two
perfect cubes is 16.7%. Because two thrombi are decidedly not perfect cubes, the critical value
must be something less than 16.7%. Experience with thrombus experiments tell us that thrombi
in contact with each other can be disjoined when only one thrombus is removed; therefore, we
know that the critical value must be greater than zero. A center point of 8% was chosen because
it is the mean of the minimum and maximum values. Values of 6% and 10% were chosen as
reasonable high and low values for corner points.
The total number of emboli was chosen as the most appropriate response variable
because it was assumed to be directly linked to the two independent variables in question. The
computer model of thrombosis/thromboembolization was run for a 2-insert flow cell (mesh
density =

) using each combination of coalescence threshold and adhesion

strength as mapped in Figure 4-12 (with 5 replicate runs of the center point to test for
variability).
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Figure 4-12 Central composite design with additional points for curvature test

From the number of emboli predicted, only those large enough to be detectable
experimentally were used for comparison with experimental results. The critical size was
estimated by considering experimental results from a laser light scattering system used in Dr.
Solen’s  laboratory  for  microemboli  detection (described below), together with a minimal
detectable volume of

taken from a calibration curve generated by Goodman[33] for

that system. Results are shown in Table 4-3.
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Table 4-3 Central composite design with tabulated results
Standard
Order
1
2
3
4
5
6
7
8
9
10
11
12
13

Adhesion
Strength
5
11
5
11
3.758
12.242
8
8
8
8
8
8
8

Coalescence
% Threshold
6
6
10
10
8
8
5.172
10.828
8
8
8
8
8

Number of
Emboli
122
145
102
115
93
132
116
87
118
114
118
118
114

Statistical Analysis of the results showed that the adhesion strength value, the
coalescence threshold value, and the square of the coalescence threshold value were significant
in predicting the total number of emboli. Fitting to a polynomial equation quantizes the effect of
both adhesion strength and coalescence threshold on the number of emboli. Regression
coefficients along with their standard errors are given in Table 4-4.

Table 4-4 Regression coefficients for number of emboli as a
function of adhesion strength and coalescence threshold
Standard Error
Term
Coefficient
of Coefficient
Constant
Adhesion
Strength

66.165

45.3729

3.798

0.8862

Coalescence %
Threshold

10.92

11.3842

(Coalescence %
Threshold)2

-1.038

0.7066

Application of these values results in a fit equation that achieves an R2 value of 81.19%
and an adjusted R2 value of 74.92%.
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The response surface can be seen in Figure 4-13 and Figure 4-14.

Figure 4-13 Response surface for number of emboli

Figure 4-14 Contour plot for number of emboli
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Experimental data were collected to determine the target number of emboli to estimate
the adhesion strength and the threshold of contact between two thrombi to signal their
coalescence for the model. Fresh human blood was passed single-pass through the flow cells.
Emboli were continually monitored downstream of the flow cell using a light-scattering
microemboli detector[50].
The flow cells were made from polyurethane tubing (Micro-Renathane, Braintree
Scientific, Braintree, MA). Short tubing segments (
were inserted into 21-inch lengths of larger tubing (

in length,
ID) spaced

ID,

OD)

apart. The

completed flow cells, containing 2 inserts, were then rinsed by perfusing them with 5% ethanol
for approximately 1 minute and then with distilled water for approximately 5 minutes.
Blood was collected by venipuncture from health human donors who had not taken
medication for 2 weeks. The blood was drawn into heparin (Baxter Healthcare Corp, Deerfield,
IL,

final concentration) in three syringes. A flow cell was then connected to each

syringe via a connection in which the entrance to the flow cell tubing was inserted directly into
the interior of the syringe. A multi-syringe pump was then used to generate

of flow

from the syringes and their connected flow cells simultaneously while the entire system was
maintained at

.

The light scattering microemboli detector monitored the number and size of the emboli
passing through the polyurethane tubing of each flow cell downstream of the inserts. Light from
a laser diode (

,

) was directed into the tubing, while the intensity of scattered

light was continuously monitored via two detectors positioned on opposite sides of the tubing at
from the incident illumination. The monitored signal was fed to a computer, and the number
and height of the disterbances (indicators of emboli) were recorded.
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Experiment
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Table 4-5 Results from flow cell experiments
Laser
Laser
Donor
Flow Cell
Detector
Detector
A
a
a
a
A
a
a
b
A
b
b
c
A
b
b
d
A
c
c
e
A
c
c
f
B
d
a
a
B
d
a
b
B
e
b
c
B
e
b
d
B
f
c
e
B
f
c
f
C
g
a
a
C
g
a
b
C
h
b
c
C
h
b
d
C
i
c
e
C
i
c
f

Number of
Emboli
221
191
255
113
105
120
172
162
208
190
77
89
174
84
324
337
45
66

Joseph  Badal,  a  researcher  in  Dr.  Solen’s  blood-material interactions lab at BYU
performed the experiments with the help of volunteer blood donors. Nine experiments were run
over three days using three blood donors; two laser channels monitored each flow cell
experiment. Number of emboli data from these experiments is shown in Table 4-5.
Experiments 15 and 16 were not included in the analysis due to problems with the
detection system noted by the researcher performing the experiment. Although there was a wide
spread of data, the 16 data points used in the analysis were sufficient to obtain a mean number of
emboli with a reasonable confidence interval. The mean number of emboli was
confidence interval of

with a

(see Figure 4-15). The variability in the experimental results reflects

the difficulty of both classifying the behavior of blood (as it varies significantly from donor to
donor) and accurately recording embolic events amid  the  “noise”  of  red  blood  cells  and  proteins  
that exist in the blood.
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Figure 4-15 Number of emboli data with 95% confidence interval

Figure 4-16 Optimization plot for adhesion strength and coalescence threshold

36

Fitting the mean value of number of emboli using the coefficients given in Table 4-4
provides estimates for the adhesion strength and coalescence threshold. The optimization was
performed in Minitab 15® (Minitab Inc., State College, PA) and can be seen in Figure 4-16.
Table 4-6 shows the estimated values of adhesion strength and coalescence threshold to
be used in the model. Using these values, the response surface predicts 96.2 emboli with a 95%
confidence interval of 87.6 – 104.8.

Table 4-6 Estimated values for thrombosis model
Estimated Values
Adhesion Strength
6.5
10.0 %
Coalescence Threshold
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5

PREDICTING THE EFFECT OF INSERT SPACING IN THE FLOW CELL

The present model is intended to independently predict the effects of device design on
thrombosis and embolization. The predictive ability of the model must be demonstrated by using
it to predict the effect of variations in a device design on resulting thrombosis and
thromboembolization. Since the value of those predictions can only be evaluated by comparison
with experimental data, an experimental setup that allows such detailed evaluation was needed.
A good candidate for such experimental work was Goodman’s  original  flow  cell,  in which the
design could be varied by changing the spacing between flow constriction inserts (e.g. Figure
5-1).

Figure 5-1 Variations on flow cell to demonstrate effect of device design

The effect of the change in the spacing between inserts must be significant enough to
alter the flow of blood through the tubing. Steady-state computational fluid dynamics
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simulations were performed to examine the effect of the spacing between inserts on the velocity
field. Flow cell models were designed in three-dimensions with inserts spaced at
, and

,

. STAR-CD® was used to solve the steady-state velocity field of blood in

the flow cell without the thrombosis and embolization routines using the SIMPLE solver
algorithm. Comparison showed that while the inserts spaced at
very similar flow fields, the insert spaced at
with inserts spaced at

and

and

resulted in

gave more distinct results. In the models
, the flow reconnected to the wall in about the same

place after exiting the first insert; however, in the model with inserts spaced at

, the flow

exiting the first insert did not reconnect to the wall before reaching the second insert, creating a
large recirculation zone (see Figure 5-2).

Figure 5-2 Effect of insert spacing on velocity field
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Based on the results of the steady-state simulations, flow cells with inserts spaced at
and

were selected because they represent a significant change in the velocity

profile in the flow cell. Results of the predictive thrombosis/thromboembolization model and the
results of analogous experiments would be compared to demonstrate  the  model’s  value  in  the  
predictions of the effects of geometry variations on thrombosis and thromboembolization.
Transient simulations of thrombosis/thromboembolization were run for a 2-insert flow
cell (mesh density =

) with inserts spaced at

and

. As in the

previous analysis the total number of emboli was chosen as the primary response variable, and
only the emboli large enough to be detectable experimentally (estimated to be those with
volumes greater than

) were used for comparison with experimental results. Other

previously used response variables such as the location of thrombosis relative to the sudden
expansion or contraction point[34] could have been used, but the total number of emboli was
chosen to better reflect the use of transient simulation vs. the previously explored steady state
CFD analysis and to take advantage of the laser detector system vs. video microscopy, which
was not always available. Results are shown in Table 5-1. The adhesion strength and coalescence
% threshold were set to

and

respectively. These values were determined based

on the analysis described in section 4.5 of this document. Results are tabulated in Table 5-1.

Table 5-1 Summary of insert spacing computational study results
Insert Spacing
Average Embolus
Total Embolus
Number of Emboli
(mm)
Volume (mm3)
Volume (mm3)
0.5
1.0

55
100

.076
.031

The results show that the flow cells with inserts spaced at

4.17
3.07

had fewer but larger

emboli resulting in an overall increase in the total volume of emboli. It is also important to note
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that at the spacing of

, the total number of emboli was very close to the predicted number

of 96.2 and within the 95% confidence interval of 87.6 to 104.8.
A map of thrombus location shows that while the general pattern is the same, the
thrombus formation in the region between inserts was observably affected by the change.

Figure 5-3 Fraction of time occupied with thrombus

Experimental data were collected to determine the effect on thrombosis and
thromboembolization of altering the spacing between inserts from
experiments to

as in the previous

. All procedures for these experiments were the same as in the previously

described experiments. Joseph Badal and Kellie Bartholomew performed the experiments with
the help of volunteer blood donors and provided the results shown in Table 5-2. For an accurate
comparison, multiple blood samples were taken from the same donor at the same time and were
run simultaneously through flow cells with inserts spaced at both

and

.

Analysis of the raw data shows high variability between flow cells. This is not surprising
since the flow cells are made by hand. Interestingly the independent variable that appeared to
have the weakest effect on the number of emboli was the insert spacing (see Figure 5-4).
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Experiment
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18

Table 5-2 Experimental data from insert spacing comparison
Experiment
Laser
Flow Cell
Spacing
Set
Detector
A
A
ch0
1.0
A
A
ch1
1.0
A
B
ch3
0.5
A
B
ch4
0.5
A
C
ch6
1.0
A
C
ch7
1.0
B
D
ch0
0.5
B
D
ch1
0.5
B
E
ch3
1.0
B
E
ch4
1.0
C
F
ch3
0.5
C
F
ch4
0.5
C
G
ch6
1.0
C
G
ch7
1.0
D
H
ch0
1.0
D
H
ch1
1.0
D
I
ch6
0.5
D
I
ch7
0.5

Figure 5-4 Main effect of all independent variables in spacing experiments
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Number of
Emboli
37
39
76
45
105
152
29
32
130
91
114
132
24
28
205
141
141
136

To isolate the effect of spacing from donor-to-donor variability, each experimental set
(involving a single donor) was analyzed separately. This is accomplished by comparing the
average effect of insert spacing for a single donor. Results are tabulated in Table 5-3.

Table 5-3 Effect of insert spacing on average number
of emboli (averaged from the data in Table 5-2)
Experiment
0.5 mm
1.0 mm
Set
60.5
83.3
A
30.5
110.5
B
123.0
26.0
C
138.5
173.0
D

The data shows a wide spread in the number of emboli for both the

and

flow cells and that the effect of the insert spacing was not consistent among experiments. These
results reflect the difficulty of categorizing the behavior of blood as it varies widely between
donors and for a single donor depending on diet, temperament, and health, and also the difficulty
in manufacturing the flow cells consistently and accurately detecting the emboli among the many
biological species that exist in blood. However, because the current model is only intended to
predict the average effect, the analysis may still be useful. A paired t-test was performed to
examine the effect of the insert spacing (see Figure 5-5). Results show an estimated population
mean difference of -10.1 with a 95% confidence interval of -130.2 to 110.1. Clearly, the data do
not offer any statistically significant effect.
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Figure 5-5 Paired t-test of average number of emboli as effected by insert spacing

Further experiments may provide a better description of the actual effect of varying the
spacing between inserts; however, it is more likely that the change in insert spacing simply did
not exert a significant effect on the thromboembolization potential. A more conclusive
demonstration of the model would require a more significant difference between the geometries
to be compared.
The comparison did show general agreement on the location of emboli initiation.
However, contrary to experimental results, the model did not predict thrombosis in the
constricted sections of the flow cell. The reader is referred to Chapter 7 of this document for
further analysis of this observation.
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6

DEMONSTRATE THE MODEL’S  USE FOR DESIGNING A HEMODIALYSIS
CATHETER

As a demonstration of the model’s  use  in  the  design  of  blood-contacting devices, the
simulation was applied to a Mahurkar blood dialysis catheter. A section of the catheter was
measured and model in SolidWorks®. Figure 6-1 shows the catheter model and  it’s  subsequent  
insertion into a flow volume representative of the superior vena cava.

Figure 6-1 Standard Mahurkar blood dialysis catheter design

The catheter is designed to take blood from the patient through the semicircular inlet and
two circular perforations. The blood then goes out to the dialysis machine and after being
cleaned is returned through the catheter outlet located beneath and downstream of the inlet
section. The present analysis deals only with the thrombosis and embolization at the catheter
inlet section, so the outlet will not be modeled here.
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The blood catheter has an outside diameter at the largest point of approximately 4.8 mm,
and the superior vena cava (the common insertion point of the catheter) has an average inside
diameter of approximately 1.5 to 2 cm. This resulted in a large percentage of the computational
volume being empty space. Reducing the diameter of the blood vessel allowed us to drastically
reduce the total computational volume without affecting the simulations results. Though care
was taken to appropriately scale the fluid velocities to maintain consistency with physiological
conditions and the no-slip condition was relaxed for the constricted blood vessel wall to avoid
it’s  interference  with  the  flow  profile  in  the  vicinity  of  the  blood  catheter.
A summary of thrombus history in the device after 330 seconds of simulation time is
shown in Figure 6-2.

Figure 6-2 Thrombus history in standard Mahurkar catheter after 330 seconds
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Originally, it was believed that the inlet holes, which force flow perpendicular to the bulk
flow path, would cause activation and deposition of platelets on the inner catheter wall. Results
show however, that at least while the device is operating, the shear rates in the inlet portion of
the catheter are too high to allow thrombus to form. A discussion of the critical shear rate used in
the program can be found in Chapter 7. Instead, we see thrombus forming in a stagnation zone
where the bulk flow splits between continuing downstream and proceeding up the catheter inlet
(see Figure 6-3).

Figure 6-3 Velocity vector field in standard Mahurkar after 330 seconds

A variation on the standard Mahurkar design was created which, it was believed, would
decrease thrombosis and embolization by redirecting the flow from the circular inlet holes to an
angle significantly less than 90°. The design can be see in Figure 6-4.
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Figure 6-4 Augmented Mahurkar blood dialysis catheter design

The results of applying the simulation to this new geometry can be seen in Figure 6-5.

Figure 6-5 Thrombus history in augmented Mahurkar catheter after 330 seconds

50

The augmented design actually predicted more thrombus formation. It is believed that
this is due to more of the total dialysis inlet flow coming through the circular perforations versus
the semicircular inlet resulting in lower flow rates in that region and longer residence times. The
velocity vector field shown in Figure 6-6 confirms this.

Figure 6-6 Velocity vector field in augmented Mahurkar after 330 seconds

While the augmented catheter design did not decrease the risk of thrombosis and
thromboembolization as was believed, the value of using a simulation for testing variations on a
device for their thrombogenic potential is apparent through this exercise. A similar study
involving in vitro or in vivo experiments would have required significantly more time and money
for presumably the same or similar results.
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7

CONCLUSION AND RECOMMENDATIONS

A multi-processor model of thrombosis and embolization was developed to aid in the
development of blood-contacting devices that minimize the risk of thrombosis and
thromboemboli. Previous work by Daniel Lattin, Jeff Ashton, and Denzel Frost formed the basis
for the model. The model was successfully written to take advantage of parallel processing.
Successful simulation of the flow of blood around developing thrombi resulted in stagnation and
high shear regions in the flow field, which greatly affect the rates of thrombosis and
embolization. A system of simulation tracking was developed to allow for detailed reporting of
real-time calculations and thrombus development. Removing unnecessary loops and calculations
further reduced runtime (approximately 50%). The model required the estimation of two key
parameters: the adhesion strength of platelets to the device wall and the threshold criterion for
coalescence of two neighboring thrombi. These parameters were estimated using statistical
analysis of a central composite design and fitting to experimental data. A preliminary validation
of the model suggests that the computational model could predict the effect of design variations
on the risk of thromboembolic events.
Further experiments are needed to adequately compare experimental observation with the
computational results. It will then be possible to make adjustments to an actual blood-contacting
device and examine the predicted effects on thrombosis and embolization. Testing a design in
this way will reduce the time and cost of designing such devices and allow for better
optimization of the geometry to reduce the risk of thrombosis and embolization.
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There are opportunities for continuing work on the design of the model algorithms.
Improvement could be made to the treatment of the effect of shear stress on platelets. The model
presented here does not take into account a  platelet’s  history.  The additive effect of shear stress
as a platelet moves along a flow path could be incorporated to better represent the possibility for
shear-mediated activation of platelets. However, some initial analysis suggests that at least in the
flow cell, shear activation is unlikely due to short residence times.
One present concern is that in the flow cell experiments it is not unusual to see thrombus
growing in the constricted section of the flow volume, while this is not seen in the computational
simulation. This is due to a shear rate threshold in the computational simulation above which
wall thrombi are not allowed to initiate. Corbett et al. [34] reported this value to be 54 s-1, but
also reported a previously established value of 10 - 20 s-1 (the present model uses 20 s-1) pointing
to several published works [46-49]. The simulation predicts shear rates in that section above
5500 s-1. Given the extremely high shear rates in the constricted section, which would make it
difficult for platelets to adhere to the wall, it is possible that the thrombi seen there started in a
lower shear region and subsequently either grew or were pushed by flow forces into the
constricted section. However it is also possible that the application of a shear rate threshold for
thrombosis leads to the inconsistency. Some recent investigation into the shear rate threshold for
thrombosis suggests that: 1) reported values may not applicable to our transient simulation
(Corbett  et  al.’s  experiments differ from hours in that they incorporated a much higher heparin
concentration, bovine blood, and a blood loop, and were evaluated at the end of a 2 hour
experiment), and 2) such a threshold may not be needed in a computational model because there
is evidence to support that such a threshold may not exist in physiological systems (the works
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cited by Corbett et al. are inconsistent in their methods and unclear in their reporting of a
threshold for thrombosis). Further investigation into this threshold parameter is needed.
Enhancements to the model could include allowing the model to predict the deformation
or rolling of thrombi as directed by flow forces; the present model does not allow for any
movement of thrombus after formation except in the case of removal due to shear forces. This
movement is often seen in experiments as thrombi deform, creep, or roll along the wall in the
direction of flow. Computationally this could be accomplished by evaluating not just the total
force on a thrombus with each time step but the vector forces and their potential for pushing,
pulling, or detaching the thrombus or a part of the thrombus. This would introduce many
complications in the definition of cells as either fluid or thrombus. As the simulated thrombus
moved in the flow field, cells would constantly need to be redefined at the thrombus-fluid
boundary. However, there is little to be gained by this possible extension of the current model as
it is meant to predict the risk of thrombosis and embolization as predicted by the flow geometry.
The transient movement of a formed thrombus is believed to contribute little to the overall
thrombogenic activity of a device.
Perhaps a better candidate for improvement would be altering the inlet velocity to more
closely reflect in vivo conditions for devices on the arterial side of a  patient’s  circulatory  system  
(e.g. coronary stents, arterial grafts, etc.). The pulsatile nature of blood flow, for example, could
be included and may prove to have a significant effect on the processes of thrombosis and
embolization due to longer residence times and circular stress patterns.
Another possible improvement to the model would be to continue to track the movement
of thrombi after embolization until they exit the flow volume. In the present model thrombi that
meet the criteria for embolization are removed instantly from the flow volume, with no effect on
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the downstream characteristics. However, it is possible that as the thrombi flow downstream they
may have a continued effect on thrombosis or embolization by affecting shear rates around or
actually coming into contact with neighboring thrombi.
A final recommendation for the further improvement of the model is to apply a
temporally dynamic cell stencil. Such a system would allow the division of cells to change with
each time step, as governed by the size of cells locally necessary to justify the assumption of
uniformity of all physical properties and accuracy of derivative evaluation within a cell. In bulk
flow areas, larger cells would be used to speed computation time while locations near a boundary
or recirculation zone would be populated with the very small cells necessary for accurate
computation. While this would necessitate the significant work of freeing the simulation from the
STAR-CD® framework, the benefits in computation time and accuracy may outweigh the costs.
While this work represents a substantial contribution to the prediction of thrombosis and
thromboembolization in blood-contacting devices, it is clear that there is still much work to be
done. This work provides insight into the factors affecting thrombosis and embolization,
especially the effect of fluid dynamics, and shows promise for effective use in the design of
blood-contacting devices that will more successfully limit the risk of thrombosis and
thromboembolization.
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APPENDIX A

FORTRAN ROUTINES

Relevant Fortran  subroutines  are  included  here  for  the  reader’s  convenience.  Subroutines  
provide ample comments to explain the calculations involved in the thrombosis and embolization
processes as well as the mechanics behind the parallel processing algorithm.

A.1 Sorsca.f
C*************************************************************************
SUBROUTINE SORSCA(S1P,S2P)
C
Source-term for scalar species
C*************************************************************************
C--------------------------------------------------------------------------*
C
STAR VERSION 4.12.033
*
C--------------------------------------------------------------------------*
INCLUDE 'comdb.inc'
COMMON/USR001/INTFLG(100)
INCLUDE 'usrdat.inc'
DIMENSION SCALAR(50)
EQUIVALENCE( UDAT12(001),
EQUIVALENCE( UDAT03(001),
EQUIVALENCE( UDAT03(002),
EQUIVALENCE( UDAT03(009),
EQUIVALENCE( UDAT03(010),
EQUIVALENCE( UDAT03(011),
EQUIVALENCE( UDAT03(012),
EQUIVALENCE( UDAT03(013),
EQUIVALENCE( UDAT03(014),
EQUIVALENCE( UDAT03(015),
EQUIVALENCE( UDAT03(016),
EQUIVALENCE( UDAT03(017),
EQUIVALENCE( UDAT03(019),
EQUIVALENCE( UDAT04(001),
EQUIVALENCE( UDAT04(002),
EQUIVALENCE( UDAT04(003),
EQUIVALENCE( UDAT04(004),
EQUIVALENCE( UDAT04(006),
EQUIVALENCE( UDAT04(008),
EQUIVALENCE( UDAT04(009),
EQUIVALENCE( UDAT04(010),
EQUIVALENCE( UDAT04(011),

ICTID )
CON )
TAU )
DUDX )
DVDX )
DWDX )
DUDY )
DVDY )
DWDY )
DUDZ )
DVDZ )
DWDZ )
VOLP )
CP )
DEN )
ED )
HP )
P )
TE )
SCALAR(01) )
SCALAR(02) )
SCALAR(03) )
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EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(
EQUIVALENCE(

UDAT04(012),
UDAT04(013),
UDAT04(014),
UDAT04(015),
UDAT04(016),
UDAT04(017),
UDAT04(018),
UDAT04(019),
UDAT04(020),
UDAT04(021),
UDAT04(022),
UDAT04(023),
UDAT04(024),
UDAT04(025),
UDAT04(026),
UDAT04(027),
UDAT04(028),
UDAT04(029),
UDAT04(030),
UDAT04(059),
UDAT04(060),
UDAT04(061),
UDAT04(062),
UDAT04(063),
UDAT04(007),
UDAT04(067),
UDAT04(068),
UDAT04(069),
UDAT09(001),

SCALAR(04)
SCALAR(05)
SCALAR(06)
SCALAR(07)
SCALAR(08)
SCALAR(09)
SCALAR(10)
SCALAR(11)
SCALAR(12)
SCALAR(13)
SCALAR(14)
SCALAR(15)
SCALAR(16)
SCALAR(17)
SCALAR(18)
SCALAR(19)
SCALAR(20)
SCALAR(21)
SCALAR(22)
U )
V )
W )
VISM )
VIST )
T )
X )
Y )
Z )
IS )

)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)
)

C----------------------------------------------------------------------C
This subroutine enables the user to specify source terms (per unit
C
volume) for species in linearized form:
C
C
Source = S1P-S2P*SCALAR(IS), (kg/sm3)
C
C
in an arbitrary manner, where S1P and S2P are returned to STAR
C
C
If the species is to be fixed to a given value SCI, then the
C
following may be used:
C
S1P=GREAT*SCI
C
S2P=GREAT
C**********
C
You MUST use the GREAT term in these equations for it to work!!
C**********
C
where SCI can be a constant or an arbitrary function of the
C
parameters in the parameter list.
C---------------------------------------------------------------------C
Sample coding 1: Fix the mass concentration of scalar 1 in fluid 2
C
to a constant value SCALAR(1)=.75
C
IF(IS.EQ.1.AND.IMAT.EQ.2) THEN
C
S1P=GREAT*.75
C
S2P=GREAT
C
ENDIF
C
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C***********************************************************************
C
Documentation Section
C***********************************************************************
C
DATE
:: 2012-03-21
C
AUTHOR
:: "Brandon Andersen" <btand@byu.edu>, Denzil Frost
C
:: Jeff Ashton,Daniel Lattin,Paul Goodman
C
VERSION
:: 5.0
C
DESCRIPTION :: Calculate source terms for all species in all cells
C
OPTIONS
:: none
C-----------------------------------------------------------------------C
Dimension Variables to be used
C-----------------------------------------------------------------------C
Variable types are not explicity defined
C-----------------------------------------------------------------------C
Redefine the various scalars with helpful names:
C-----------------------------------------------------------------------yPl = SCALAR(01)
C
platelet mass fraction
yaPl = SCALAR(02)
C
activated platelet mass fration
yADP = SCALAR(03)
C
ADP mass fraction
yTxA2 = SCALAR(04)
C
Thromboxane A2 mass fraction
ypT = SCALAR(05)
C
proThrombin mass fraction
yT = SCALAR(06)
C
Thrombin mass fraction
yaT = SCALAR(07)
C
antiThrombin III mass fraction
nBldSt = SCALAR(08)
C
blood status of the cell (see key above)
C
0 - interior fluid
C
1 - wall fluid
C
2 - wall thrombus
C
3 - interior thrombus
C
4 - interior fluid with thrombus neighbor
C
5 - wall fluid with thrombus neighbor
C
6 - blood vessel wall fluid
ThrFr = SCALAR(09)
C
Thrombus fraction (1=thrombus,0=fluid)
actFr = SCALAR(10)
C
(s) - Time for activation by shear stress
ShrRt = SCALAR(11)
C
(1/s) Shear Rate, calculated in scalfn.f
xM = SCALAR(15)
C
(Pl/m2) platelet concentration on surface
xMact = SCALAR(16)
C
(Pl/m2) activated platelet concentration on surface
Xact = SCALAR(17)
C
fraction of active platelets
Sp = SCALAR(18)
C
fraction of surface not cover by platelets
PlSrc = SCALAR(19)
C
(kg/m3-s) platelet source term (+ to fluid)
aPlSrc = SCALAR(20)
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C
C
C

-

(kg/m3-s) activated platelet source term (+ to fluid)
pulse = SCALAR(21)
(Pl/m2) platelets activated at actFr = 1
nPlsFl = SCALAR(22)
activation flag (1=reached on this/prev)

C-----------------------------------------------------------------------C
Define Constants
C-----------------------------------------------------------------------wADP = 1
C
weighting factor for ADP in chemical activation
wTxA2 = 1
C
weighting factor for TxA2 in chemical activation
wT = 1
C
weighting factor for Thrombin in chemical activation
cADP = 2E-3
C
(mol/m3) critical concentration of ADP
ADPmw = .424
C
(kg/mol) molecular weight of ADP
cTxA2 = 6E-4
C
(mol/m3) critical concentration of TxA2
TxA2mw = 0.353
C
(kg/mol) molecular weight of TxA2
cT = 3.7E-6
C
(kg/m3) critical concentration of Thrombin
BldDens = 1056
C
(kg/m3) - density of blood
PltMass = 2.12E-15
C
(kg/platelet) - mass of single blood platelet
tact = 1.0
C
(s) characteristic time constant for activation
rlambda = 1.02E-17
C
(kg ADP/plt) ADP released by activation of platelet
C
from 2.4E-8 nmol ADP/platelet (pg.63 of D)
C
and MW ADP = 0.4244 kg ADP/gmol
C
--DT
C
(s) time step size
st = 3.35E-21
C
(kg TxA2/aPlt-s) rate of production of TxA2
C
from 9.5E-12 nmol TxA2/platelet-s (pg.61 of D)
C
and MW TxA2 = 0.3525 kg TxA2/gmol
rki = 0.0161
C
(1/s) rate constant for hydrolyxation of TxA2 to TxB2
C
see pg.61 of D
PltVol = 1.02e-17
C
(m3/platelet) - volume of a sigle blood platelet
C
(assumed equal for active and resting platelets)
xThVd = 0.2
C
ASSUMED Void fraction in a thrombus
PHIat = 3.36E-17
C
(m3/aplt*s)
C
3.69*10^-9 units/plt*s*microM pT) (pg.64 of D)
C
*(9.11*10^-6 micromol pT/unit)(1 m3/1000*L)
C
= 3.36*10^-17 m3/plt*s
PHIrt = 5.92E-18
C
(m3/rplt*s)
C
PHIrt = 6.5*10^-10 units/plt*s*microM pT) (pg.64 of D)
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C
C

-

C

-

C

-

C

-

C

-

C
C

-

C

-

C

-

*(9.11*10^-6 micromol pT/unit)(1 m3/1000*L)
= 5.92*10^-18 m3/plt*s
xTpT = .508

(kg_T/mol_T) / (kg_pT/mol_pT)

rk1t = 13.33

(1/s) first order rate constant
rKat = 1.0E-04
(mol/m3) dissociation constant for heparin/T complex
rKt = 3.5E-05
(mol/m3) dissociation constant for heparin/aT complex
H = .5*1.388*(10**-4)
(mol/m3) concentration of heparin
this is equal to .5 units/mL
aTmw = 58.2
(kg/mol) molecular weight of antiThrombin III
Tmw = 36.0
(kg/mol) molecular weight of Thrombin

C----------------------------------------------------------------------C
Files for output
C----------------------------------------------------------------------infoFile = 61
C

Tracking File
myIP = 0
trkFile = infoFile
C
trkFile = 89
C
open(unit=trkFile, file="mySorsca.txt")
IF(myIP.EQ.IP) THEN
C
IF(IS.EQ.1) THEN
C
IF(ITER.EQ.1) THEN
write(trkFile,410) 'LB','TIME','yPl','yaPl','yADP','yTxA2'
$
,'ypT','yT','yaT'
410
format(A2,A6,A11,A11,A11,A11,A11,A11,A11)
C
ENDIF
write(trkFile,420) 'SR',TIME,yPl,yaPl,yADP,yTxA2,ypT,yT,yaT
420
format(A2,F6.2,D11.4,D11.4,D11.4,D11.4,D11.4,D11.4,D11.4)
C
ENDIF
ENDIF
C----------------------------------------------------------------------C
Source Term Calculation
C----------------------------------------------------------------------C
Initialize the source terms (S1P & S2P) to 0.0
S1P = 0.0
S2P = 0.0
C----------------------------------------------------------------------C
Agonist-Induced Platelet Activation
pgs. 59-60 of Dissertation
C----------------------------------------------------------------------IF(myIP.EQ.IP) write(trkFile,*) '-------------------------------'
IF(myIP.EQ.IP) write(trkFile,*) 'IS = ',IS
C
omega = sum (w.j *(a.j/a.j,crit))
omega = BldDens*(yADP/cADP/ADPmw + yTxA2/cTxA2/TxA2mw + yT/cT)
IF(myIP.EQ.IP) write(trkFile,*) 'omega = ',omega
IF (omega.GE.1) THEN
C
if omega < 1.0, kpa (1/s) = 0 (called ratec here)
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C

C

ratec = omega/tact
ELSE
else kpa (1/s) = omega/t.act (called ratec here)
ratec = 0
ENDIF
IF(myIP.EQ.IP) write(trkFile,*) 'ratec = ',ratec
Pl_src (kg/m3-s)
Pl_src = ratec*yPl*BldDens
IF(myIP.EQ.IP) write(trkFile,*) 'Pl_src = ',Pl_src

C----------------------------------------------------------------------C
Unactivated Platelets
C----------------------------------------------------------------------IF (IS.EQ.1) THEN
C
Plt (kg_rPlt/m3-s)
IF (nBldSt.EQ.2.OR.nBldSt.EQ.3) THEN
C
No change in fluid concentration of resting platelets in thrombus
S1P = 0.0
ELSE
C
Resting platelet conc change in fluid by chemical activation and
C
transport to the wall
S1P = -Pl_src + PlSrc
ENDIF
C----------------------------------------------------------------------C
Activated Platelets
C----------------------------------------------------------------------ELSEIF (IS.EQ.2) THEN
C
aPlt (kg_aPlt/m3-s)
IF (nBldSt.EQ.2.OR.nBldSt.EQ.3) THEN
C
No change in fluid concentration of active platelets in thrombus
S1P = 0.0
ELSE
C
Active platelet conc change in fluid by chemical activation and
C
transport to the wall
S1P = Pl_src + aPlSrc
ENDIF
C----------------------------------------------------------------------C
ADP (see pg. 21 of AC and pg. 59-61 of D) --Same no matter where
C----------------------------------------------------------------------ELSEIF (IS.EQ.3) THEN
C
ADP (kg_ADP/m3-s)
C
ADP released from agonist-activated platelets
S1P = rlambda*Pl_src/PltMass
C
ADP released from platelets activated by adhearing to wall or
C
thrombus
S1P = S1P + -PlSrc/PltMass*rlambda
IF (nPlsFl.EQ.1) THEN
C
ADP released from shear-activated surface platelets (Hellums' Eq.)
S1P = S1P + rlambda*pulse/VOLP/DT
ENDIF
C----------------------------------------------------------------------C
Thromboxane A2 (see pg. 21 of AC and pgs. 59,61 of D)
C----------------------------------------------------------------------ELSEIF (IS.EQ.4) THEN
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C
C
C
C

TxA2 (kg_TxA2/m3-s)
TxA2 synthesized in active platelets adheared to surface or wall
S1P = st*(1-xThVd)*ThrFr*Xact/PltVol
IF (nBldSt.NE.2.AND.nBldSt.NE.3) THEN
TxA2 synthesized in active platelets in bulk fluid
S1P = S1P + st*yaPl*BldDens/PltMass
ENDIF
TxA2 converted to TxB2 by de-activation
S1P = S1P - rki*yTxA2*BldDens

C----------------------------------------------------------------------C
Prothrombin (see pg. 21 of AC and pgs. 59,61-62,64 of D)
C----------------------------------------------------------------------ELSE IF (IS.EQ.5) THEN
C
pT (kg pT/m3-s)
C
proThrombin consumed in production of Thrombin at platelet surfaces
C
of platelets adhered to platelets or walls
S1P = -ypT*BldDens*(PHIat*(1-xThVd)*ThrFr*Xact+PHIrt*(1-xThVd)
$
*ThrFr*(1-Xact))/PltVol
IF (nBldSt.NE.2.AND.nBldSt.NE.3) THEN
C
proThrombin consumed in the production of Thrombin at platelet
C
surfaces of platelets in bulk fluid
S1P = S1P - ypT*BldDens*(PHIat*yaPl+PHIrt*yPl)*BldDens/PltMass
ENDIF
C----------------------------------------------------------------------C
Thrombin in Bulk (see pg. 22 of AC and pgs. 59,61-62 of D)
C----------------------------------------------------------------------ELSE IF (IS.EQ.6) THEN
C
tgen (kg_T/m3-s)
C
Generation of thrombin by proThrombin inside thrombus at surface of
C
platelets
tgen = ypT*BldDens*(PHIat*(1-xThVd)*ThrFr*Xact+PHIrt*(1-xThVd)
$
*ThrFr*(1-Xact))*xTpT/PltVol
C
tloss (kg_T/m3-s) = Gamma * [T]
C
heparin-catalyzed inactivation of Thrombin by antiThrombin III in
C
bulk fluid and thrombus
tloss = rk1t*H*yaT*BldDens*yT*BldDens/(aTmw*(rKat*rKt + rKat*yT
$
*BldDens/Tmw + rKt*yaT*BldDens/aTmw + yaT*yT*BldDens*BldDens
$
/(aTmw*Tmw)))
IF (nBldSt.NE.2.AND.nBldSt.NE.3) THEN
C
generation of thrombin by prothrombin at platelet surfaces in bulk
C
fluid
tgen = tgen + ypT*BldDens*(PHIat*yaPl+PHIrt*yPl)*BldDens*xTpT
$
/PltMass
ENDIF
C
T (kg_T/m3-s) = tgen - tloss
S1P = tgen - tloss
C----------------------------------------------------------------------C
antiThrombin III (see pg. 22 of AC and pgs. 59,61-64 of D)
C----------------------------------------------------------------------ELSE IF (IS.EQ.7) THEN
C
aT (kg_aT/m3-s) = -Gamma*[T]*aTmw/Tmw
C
Consumption of antiThrombin III to inactivate Thrombin in bulk fluid
C
and thrombus
S1P = -rk1t*H*yaT*BldDens*yT*BldDens/(aTmw*(rKat*rKt + rKat*yT
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$
$

*BldDens/Tmw + rKt*yaT*BldDens/aTmw + yaT*yT*BldDens*BldDens
/(aTmw*Tmw)))*aTmw/Tmw
ENDIF
IF(myIP.EQ.IP) write(trkFile,*) 'S1P = ',S1P
IF(myIP.EQ.IP) write(trkFile,*) 'S2P = ',S2P
RETURN
END

A.2 Posdat.f
c***********************************************************************
subroutine posdat(level)
c
Post-process data
C***********************************************************************
C----------------------------------------------------------------------C
STAR-CD VERSION 4.16.000
C----------------------------------------------------------------------USE allmod
USE aaaUsrMod
USE timeParallel, ONLY: globalMaster
IMPLICIT NONE
INCLUDE 'std.inc'
C----------------------------------------------------------------------C
C
This subroutine enables the user to output data and is called
C
at the beginning and at the end of each iteration/time step,
C
i.e.
C
if (level.eq.1) then
c.>
called at the beginning of iteration/time step
C
else if (level.eq.2) then
c.>
called at the end of iteration/time step
C
end if
C
Any user code which is not enclosed in the IF condition will
C
be executed for both calls
C
C
Note: 1. File units available to the users for opening their own
C
files are from 84 to 89. Users may write to unit 6 or 60
C
if they want to see their output on the terminal or
C
the run file.
C
2. All variables passed to this routine use STAR cell
C
numbering, which is different from pro-STAR cell numbers.
C
pro-STAR cell number can be obtained from a STAR cell
C
number ICSTAR by ICPROSTAR=ICLMAP(ICSTAR)
C----------------------------------------------------------------------C***********************************************************************
C
Documentation Section
C***********************************************************************
C
DATE
:: 2012-03-21
C
AUTHOR
:: "Brandon Andersen" <btand@byu.edu>, Denzil Frost
C
:: Jeff Ashton,Daniel Lattin,Paul Goodman
C
VERSION
:: 5.0
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C
C
C

DESCRIPTION ::
::
OPTIONS
::

calculate platelet adhesion to walls and thrombi,
manage thrombosis and embolization
none

C----------------------------------------------------------------------C
Functions/Calls Used
C----------------------------------------------------------------------C
### regi(nr)%type
C
Returns the type of region nr
C
C

### Call FsetBoun(fs,0,ND_ALL,NSD_ALL,nr,ISIDE_ALL)
Creates a set of faces (fs) that meet some criteria

C
C

### lfs(1,IS)
Identifies the cell on the inside(1) of the boundary face IS

C
C

### Call cset(cs,0,nd,NSD_ALL,INTERNAL)
Returns a set of cells (cs) that meet some criteria

C
C
C
C
C
C
C
C
C
C
C
C
C

### call arrSwap(var,nd,index,icomp,FSFLAG)
provided by Senthil Dhanapalan at CD Adapco
Swaps the values of the selected variables between the cells on the
boundary of each processor domain with the cells just beyond that
boundary (halo cells for that processor)
var(*),var(*,*):integer,single/double precision array to be swapped
nd
: swap data of domain nd
index
: element (1, 2, 3...) in the array list that is to be fixed
icomp
: component to be fixed
e.g. index=1, icomp=2 => send var(2,:),
or index=2, icomp=7 => send var(:,7)
FSFLAG : Allowed values are FLUID,SOLID,FLSOL (1,2,3)
swap only if the domain is F,S or both

C
C

### GSUM(localVariable) --see star_uguide.pdf Appendix D
Returns the real/double sum of 'localVariable' from all processors

C
C

### IGSUM(localVariable) --see star_uguide.pdf Appendix D
Returns the integer sum of 'localVariable' from all processors

C
C
C
C

### Call LGLOR(locLogical,glblLogical) --see star_uguide.pdf
Appendix D
Returns the OR result of comparing all 'locLogical' and stores it
as 'glblLogical'

C----------------------------------------------------------------------C
User Defined Arrays
C----------------------------------------------------------------------C
:: ThrArray(row) :: is a global array (updated on all processors)
C
in which the IDs (ThrNum) of all active thrombi are stored
C
C
C

:: ThrLoc(row) :: is a local array (populated separately by each
processor and cleared after each time step) in which the IDs
(iThrNum) of new thrombi within that processor are stored

C
C

:: ThrMap(iThrNum) :: is a global array (updated on all processors)
that returns the row of ThrArray in which iThrNum is stored
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C
C

:: ThrLg(nT) :: is a logical that tells if any INTERNAL cell
in the processor belongs to the thrombus 'nT'

C
C

:: ThrLgH(nT) :: is a logical that tells if any HALO cell for
the processor belongs to the thrombus 'nT'

C
C
C

:: ThrMP(nT) :: is a logical array that identifies a thrombus
that exists on multiple processors (only one processor
will correctly identify the thrombus as .TRUE.)

C
C

:: ThrSA(nT) :: is Real array that temporarily stores the area
of some thrombus that touches a neighboring thrombus nT

C
C

:: c_old(ic) :: is a real array that stores calculation
temporarily to compare to what is returned from the arrSwap

C
C

:: c_old2(ic) :: is a real array that stores calculation
temporarily to compare to what is returned from the arrSwap

C
C
C

:: NeArray(row) :: is a global array (updated on all processors)
in which the IDs (ThrNum) of all thrombi which are neighbors to the
thrombus being analyzed are temporaily stored

C***********************************************************************
C
Code Section
C***********************************************************************
C----------------------------------------------------------------------C
Dimension REAL and INTEGER variables to be used
C----------------------------------------------------------------------REAL(ra) actT,AdhStrs,apadhm,athromb
REAL(ra) BldDens,BldStSet,BldVisc,CoalArea,cVol,deltha,delthu
REAL(ra) frpremain,height,kas,kt,kus,MAX,myTime
REAL(ra) nbraPlt,nbrPlt,nbrXact,percCA,PltMass,PltVol
REAL(ra) SA1,SAsum,SAthromb,shearfc,sheartot,surfarea
REAL(ra) Threshold,upadhm
REAL(ra) uthromb,vthromb,vtot,xMinf,xThVd
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
INTEGER

iactFr,iaPlSrc,IC,iEmbVol,iIHPC,iNumEmb,inBldSt
iArBnd,iArThr,inPlsFl,iPlSrc,iPLTadh,ipulse
IS,iShrRt,iSp,iThrNum,iThrFr,iFrTmThr
iviscosity,ixM,ixMact,iXact,iyPl,iyaPl,level
MAXNBR,NBRCLL,ncount,nd,nf,nfs,nr,nset,nT,nT1
Thrneighbor

INTEGER
INTEGER
INTEGER
INTEGER
INTEGER
LOGICAL
LOGICAL

allocatestatus,GNCELL,itMax,itNum
infoFile,embFile,errFile,trkFile
intMax,intMin,it,MAXROW
myCell,myICLMAP,myRow,myThromb,myVar,numZero
row,row1,row2,vThrFile
CmbThr,CmbThrG,EmbThr,EmbThrG,errDiag,errFnd
needSwap,needSwapG,ThrMPG

C----------------------------------------------------------------------C
Cell property storage location in array c(cell,properties)
C----------------------------------------------------------------------iyPl = 1
C
platelet mass fraction
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C

-

C
C
C
C
C
C
C
C
C

-

C

-

C

-

C

-

C
C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

iyaPl = 2
activated platelet mass fraction
inBldSt = 8
blood status of the cell (see key above)
0 - interior fluid
1 - wall fluid
2 - wall thrombus
3 - interior thrombus
4 - interior fluid with thrombus neighbor
5 - wall fluid with thrombus neighbor
6 - blood vessel wall fluid
7 - flow outlet (assigned temporarily)
iThrFr = 9
Thrombus fraction (1=thrombus,0=fluid)
iactFr = 10
Fractional progression toward shear activation
iShrRt = 11
(1/s) Shear Rate, calculated in scalfn.f
iIHPC = 12
stores the processor number to which the cell belongs
or a zero if the cell is on a boundary between processors
iArBnd = 13
(m2) Contact area of the cell against a boundary
iArThr = 14
(m2) Contact area of the cell against a thrombus
ixM = 15
(Pl/m2) Platelet concentration on surface
ixMact = 16
(Pl/m2) Activated platelet concentration on surface
iXact = 17
Fraction of active platelets
iSp = 18
Fraction of surface not cover by platelets
iPlSrc = 19
(kg/m3-s) Platelet source term (+ to fluid)
iaPlSrc = 20
(kg/m3-s) Activated platelet source term (+ to fluid)
ipulse = 21
(Pl) Platelets activated upon shear activation
inPlsFl = 22
Shear Activation flag (1=reached on this/prev)
iPLTadh = 23
(Pl/s) Platelet adhesion rate (+ to wall)
iThrNum = 24
Thrombus to which this cell belongs
iNumEmb = 25
Total number of times the cell has embolized
iFrTmThr = 26
Fraction of time the cell has been thrombus
iEmbVol = 27
Average volume of emboli from this cell
iviscosity = 28
(kg/m-s,poise) Viscosity of cell

C----------------------------------------------------------------------C
Program Constants
C-----------------------------------------------------------------------
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C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

C

-

BldDens = 1056
(kg/m3) - Density of blood
BldVisc = 0.0035
(Pa*s) - Viscosity of blood
kas = 0.0035
(m/s) - Rate constant, activated platelets to wall
kt = 3.5E-3
(m/s) - Rate constant, platelets to adhered platelets
kus = 0.0000025
(m/s) - Rate constant, unactivated platelets to wall
PltMass = 2.12E-15
(kg/platelet) - Mass of single blood platelet
PltVol = 1.02e-17
(m3/platelet) - Volume of a single blood platelet
Pi = 3.1415926
(radians) Value of pi
xMinf = 1.132E11
(Pl/m2) Maximum possible platelet surface coverage
xThVd = 0.2
ASSUMED Void fraction in a thrombus
AdhStrs = 6.5000
(N/m2,Pa) - Adhesion expressed as Stress
CoalArea = 0.10
Fractional Thr SA that must be shared for coalescence
itMax = 10
Maximum number of allowed iterations for swap
GNCELL = IGSUM(NCELL)
Total number of cells in the model

C----------------------------------------------------------------------C
Files for output
C----------------------------------------------------------------------infoFile = 61
C---Embolism File
embFile = infoFile
C
embFile = 86
C
open(unit=embFile, file = "myEmboli.txt", position='append')
C---Total Thrombus Volume File
vThrFile = 87
open(unit=vThrFile, file = 'myThromb.txt', position='append')
C----------------------------------------------------------------------C
CODE EXECUTED
C----------------------------------------------------------------------IF(level.EQ.1) THEN
C#######################################################################
C
DO THE FOLLOWING IN THE FIRST CALL TO POSDAT (ie BEFORE CALCULATION)
C----------------------------------------------------------------------C
DO THE FOLLOWING AT THE BEGINNING OF THE FIRST TIME STEP
IF(ITER.EQ.1) THEN
C

Allocate memory for the user defined arrays
ALLOCATE(ThrLg(1:GNCELL),stat=allocatestatus)
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$

$

$

$

$

$

$

$

$

$

if (allocatestatus.ne.0) stop
'*** not enough memory for ThrLg() array ***'
Do row=1,GNCELL
ThrLg(row) = 0
Enddo
ALLOCATE(ThrLgH(1:GNCELL),stat=allocatestatus)
if (allocatestatus.ne.0) stop
'*** not enough memory for ThrLgH() array ***'
Do row=1,GNCELL
ThrLgH(row) = 0
Enddo
ALLOCATE(ThrLoc(1:NCELL),stat=allocatestatus)
if (allocatestatus.ne.0) stop
'*** not enough memory for ThrLoc() array ***'
Do row=1,NCELL
ThrLoc(row) = 0
Enddo
ALLOCATE(ThrMP(1:GNCELL),stat=allocatestatus)
if (allocatestatus.ne.0) stop
'*** not enough memory for ThrMP() array ***'
Do row=1,GNCELL
ThrMP(row) = 0
Enddo
ALLOCATE(ThrMAP(1:GNCELL),stat=allocatestatus)
if (allocatestatus.ne.0) stop
'*** not enough memory for ThrMAP() array ***'
Do row=1,GNCELL
ThrMAP(row) = 0
Enddo
ALLOCATE(ThrArray(1:GNCELL),stat=allocatestatus)
if (allocatestatus.ne.0) stop
'*** not enough memory for ThrArray() array ***'
Do row=1,GNCELL
ThrArray(row) = 0
Enddo
ALLOCATE(ThrSA(1:GNCELL),stat=allocatestatus)
if (allocatestatus.ne.0) stop
'*** not enough memory for ThrSA() array ***'
Do row=1,GNCELL
ThrSA(row) = 0
Enddo
ALLOCATE(c_old(1:GNCELL),stat=allocatestatus)
if (allocatestatus.ne.0) stop
'*** not enough memory for c_old() array ***'
Do row=1,GNCELL
c_old(row) = 0
Enddo
ALLOCATE(c_old2(1:GNCELL),stat=allocatestatus)
if (allocatestatus.ne.0) stop
'*** not enough memory for c_old2() array ***'
Do row=1,GNCELL
c_old2(row) = 0
Enddo
ALLOCATE(NeArray(1:NCELL),stat=allocatestatus)
if (allocatestatus.ne.0) stop
'*** not enough memory for NeArray() array ***'
Do row=1,NCELL
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NeArray(row) = 0
Enddo
C
C

C

C

Populate the iIHPC value for all cells in the model. IHPC
identifies the processor to which the cell has been assigned
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,INTERNAL)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c(IC,iIHPC) = IHPC
enddo
enddo
enddo
Make the iIHPC value 0 for cells on a processor boundary
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
do nf=1,c2f(IC)%No
IS = c2f(IC)%List(nf)
Ignore negative (boundary) faces
IF(IS.GT.0) THEN
do nfs=1,2
IF(lfc(nfs,IS).NE.IC) THEN
NBRCLL = LFC(nfs,IS)
c(NBRCLL,iIHPC) = 0
ENDIF
enddo
ENDIF
enddo
enddo
enddo
enddo

C
C
C

All boundary cells are identifed by finding all boundary faces and
then their corresponding cells. The blood status of cells next to a
wall (or a blood vessel) is set.
itNum = 0
10
continue
itNum = itNum + 1
C
The c_old2 array is used to tell if a cell started the iteration
C
with blood status not set as a wall cell. This is useful after the
C
swap to prevent doubling the area of all cells against the boundary
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
IF(c(IC,inBldSt).EQ.0.0) then
c_old2(IC) = 0.0
ELSE
c_old2(IC) = 1.0
ENDIF
enddo
enddo
enddo
C
For cells against the boundary, change blood status and calculate
C
area against the boundary
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do nr=0,regi_no
if(regi(nr)%type.EQ.WALL) then
if(nr.EQ.1) BldStSet = 1.0
if(nr.EQ.5) BldStSet = 6.0
call FsetBoun(fs,0,ND_ALL,NSD_ALL,nr,ISIDE_ALL)
do nset=1,fs%no
do IS=fs%ns(nset), fs%ne(nset)
IC = lfc(1,IS)
c_old(IC) = BldStSet
IF(c_old2(IC).EQ.0.0) THEN
c(IC,inBldSt) = BldStSet
c(IC,iArBnd) = c(IC,iArBnd) + sqrt(sv(1,IS)**2+sv(2,IS)
$
**2+sv(3,IS)**2)
ENDIF
enddo
enddo
endif
enddo
C
Populate the c_old array for halo cells (loop above only populates
C
internal cells)
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c_old(IC) = c(IC,inBldSt)
enddo
enddo
enddo
C
If this is a parallel run, swap/assign repeatedly until the BldSt
C
values stop changing
if (parrun) then
needSwap = .FALSE.
C
Perform swap for Blood Status and area against a boundary
do nd=1,doma_no
call arrSwap(c,nd,2,inBldSt,FLUID)
call arrSwap(c,nd,2,iArBnd,FLUID)
end do
c
Check if the field values have changed in this processor
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
if (c(IC,inBldSt).ne.c_old(IC).AND.itNum.lt.itMax) then
needSwap = .TRUE.
goto 15
endif
end do
end do
end do
15
continue
C
If field values changed on any processor, perform swapp again
call LGLOR(needSwap,needSwapG)
if(needSwapG) goto 10
end if
C
Clear out c_old and c_old2 arrays
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
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call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c_old(IC) = 0
c_old2(IC) = 0
enddo
enddo
endif
ENDDO
C

C

C
C

C

Exclude outlet region from calculations
do nr=0,regi_no
if(regi(nr)%type.EQ.2) then
call FsetBoun(fs,0,ND_ALL,NSD_ALL,nr,ISIDE_ALL)
do nset=1,fs%no
do IS=fs%ns(nset), fs%ne(nset)
IC = lfc(1,IS)
c(IC,inBldSt) = 7
enddo
enddo
endif
enddo
do it=1,30
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
if(c(IC,inBldSt).EQ.7) then
do nf=1,c2f(IC)%No
IS = c2f(IC)%List(nf)
Ignore negative (boundary) faces
IF(IS.GT.0) THEN
do nfs=1,2
IF(lfc(nfs,IS).NE.IC) THEN
NBRCLL = LFC(nfs,IS)
c(NBRCLL,inBldSt) = 7
ENDIF
enddo
ENDIF
enddo
endif
enddo
enddo
enddo
If this is a parallel run, swap values between processors
if (parrun) then
Perform swap for Blood Status
do nd=1,doma_no
call arrSwap(c,nd,2,inBldSt,FLUID)
end do
end if
enddo
Replace blood status 7 with blood status 0
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
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if(c(IC,inBldSt).EQ.7) then
c(IC,inBldSt) = 0
endif
enddo
enddo
enddo
C----------------------------------------------------------------------C----------------------------------------------------------------------C
DO THE FOLLOWING AT THE BEGINNING OF ALL TIME STEPS (AFTER 1ST)
ELSE
C

Loop through all of the cells
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,INTERNAL)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
delthu = 0.0
deltha = 0.0
c(IC,iPlSrc) = 0.0
c(IC,iaPlSrc) = 0.0
c(IC,iPLTadh) = 0.0

C

Update the fraction of time filled with thrombus value
if(c(IC,inBldSt).EQ.2.OR.c(IC,inBldSt).EQ.3) then
c(IC,iFrTmThr) = (c(IC,iFrTmThr)*(TIME-DT)+DT)/TIME
endif

C
C
C
C

Calculate the progression toward time of activation of thrombus. Use
Hellums' equation (see pp. 73 of dissertation) where 0.035 is the
viscosity of blood in POISE. This equation requires that the shear
rate be in units of s^-1
IF((c(IC,inBldSt).EQ.1.AND.c(IC,iShrRt).LT.20).OR.(c(IC
$
,inBldSt).GE.2.AND.c(IC,inBldSt).LE.5)) THEN
IF(c(IC,iShrRt).GT.0.0) THEN
Calculate the total time required for activation at the current
conditions
actT = 4.0E6*(c(IC,iShrRt)*0.035)**(-2.3)
Calculate the change in the overal progression toward shear
activation
c(IC,iactFr) = c(IC,iactFr) + DT/actT
ENDIF
ENDIF

C
C
C
C

C
C
C
C
C
C

If shear activation has been achieved
IF(c(IC,iactFr).GE.1.0) THEN
If the cell is not already activated
IF(c(IC,inPlsFl).EQ.0.0) THEN
Calculate the "pulse" of activated platelets and set pulse flag.
c(IC,ipulse) = VOL(IC)*c(IC,iThrFr)*(1-c(IC,iXact))*(1
$
-xThVd)/PltVol
Change the pulse flag for when activation time has been reached.
c(IC,inPlsFl) = 1.0
Set the activated concentration to the total concentration and
fraction activated to 1.
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C

c(IC,ixMact) = c(IC,ixM)
c(IC,iXact) = 1.0
If the cell was activated in the previous time step, reset values
ELSEIF (c(IC,inPlsFl).EQ.1.0) THEN
c(IC,ipulse) = 0.0
c(IC,inPlsFl) = 0.0
c(IC,iactFr) = 0.0
ENDIF
ENDIF

C
C
C
C
C
C
C

Calculate source terms for Pl, aPl--store as scalars for use in
sorsca.f
The restriction has been made that for wall fluid to undergo these
calculations, the shear rate must be less than 20 1/s This comes
from work by Hubbell and McIntire. Visualization and analysis of
mural thrombogenesis on collagen, polyurethane and nylon.
Biomaterials 1986;7:354-63 (mentioned in Corbett et al.,2010)
IF((c(IC,inBldSt).EQ.1.0.AND.c(IC,iShrRt).LT.20).OR.c(IC
$
,inBldSt).EQ.5.0.OR.c(IC,inBldSt).EQ.4.0) THEN
uthromb = 0.0
athromb = 0.0
upadhm = 0.0
apadhm = 0.0
cVol = VOL(IC)

C
C
C
C
C

Calculate the fraction of platelets that do not embolize in the time
step (frpremain). This comes from Goodman's data making the
assumption that the removal of platelets under a shear force is
instantaneous
-3.325e-4(s) = -.0095(cm2/dyn)*.035(poise)
frpremain = EXP(-3.325e-4*c(IC,iShrRt))

C----------------------------------------------------------------------C
DO THE FOLLOWING CALCULATIONS ONLY FOR WALL FLUID
IF(c(IC,inBldSt).EQ.1.0.OR.c(IC,inBldSt).EQ.5.0) THEN
C
C

Calculate the mass rate of resting platelets adhering to the wall
upadhm (kg/s) = -c(IC,iSp)*kus*[Pl]*c(IC,iArBnd)
upadhm = -c(IC,iSp)*kus*c(IC,iyPl)*BldDens*c(IC,iArBnd)
$
*frpremain

C
C

Calculate the mass rate of active platelets adhering to the wall
apadhm (kg/s) = -c(IC,iSp)*kas*[aPl]*c(IC,iArBnd)
apadhm = -c(IC,iSp)*kas*c(IC,iyaPl)*BldDens*c(IC,iArBnd)
$
*frpremain

C
C
C

Calculate the rate of unactivated platelets adhering to activated
platelets on the surface (i.e. forming uthrombs)
uthromb (kg/s) = -Mact/Minf*kt*[aPl]*c(IC,iArBnd)
uthromb = -c(IC,iXact)*(1-c(IC,iSp))*c(IC,iArBnd)*kt*c(IC
$
,iyPl)*BldDens*frpremain

C
C
C

Calculate the rate of activated platelets adhering to activated
platelets on the surface
athromb (kg/s) = -Mact/Minf*kt*[aPl]*c(IC,iArBnd)
athromb = -c(IC,iXact)*(1-c(IC,iSp))*c(IC,iArBnd)*kt*c(IC
$
,iyaPl)*BldDens*frpremain

80

C

Calculate the surface concentration of platelets (Plt/m2)
c(IC,ixM) = c(IC,ixM) - (upadhm + apadhm)*DT/PltMass
$
/c(IC,iArBnd)
IF(c(IC,ixM).LT.0.0) c(IC,ixM) = 0.0
IF(c(IC,ixM).GT.xMinf) c(IC,ixM) = xMinf

C

Calculate the fraction of boundary area free of platelets
c(IC,iSp) = 1 - (c(IC,ixM)/xMinf)

C

Calculate the surface concentration of active platelets (Plt/m2)
c(IC,ixMact) = c(IC,ixMact) - (apadhm)*DT/PltMass
$
/c(IC,iArBnd)
IF(c(IC,ixMact).GT.c(IC,ixM)) c(IC,ixMact) = c(IC,ixM)
IF(c(IC,ixMact).LT.0) c(IC,ixMact) = 0.0
ENDIF

C----------------------------------------------------------------------C
DO THESE CALCULATIONS ONLY FOR FLUID WITH THROMBUS NEIGHBOR
IF(c(IC,inBldSt).EQ.4.0.OR.c(IC,inBldSt).EQ.5.0) THEN
C
If the thrombus is new (so that we don't know anything about the
C
relative number of active vs resting platelets to which platelets
C
may adhere) then find the Xact of the neighboring thrombus cells.
IF(abs(c(IC,iXact)).LT.1E-16) THEN
nbrPlt = 0
nbraPlt = 0
nbrXact = 0
do nf=1,c2f(IC)%No
IS = c2f(IC)%List(nf)
C
Ignore negative (boundary) faces
IF(IS.GT.0) THEN
do nfs=1,2
IF(lfc(nfs,IS).NE.IC) THEN
NBRCLL = LFC(nfs,IS)
IF(c(NBRCLL,iThrNum).GT.1E-4) THEN
nbrPlt = nbrPlt + VOL(NBRCLL)*(1-xThVd)
nbraPlt = nbraPlt + VOL(NBRCLL)*(1-xThVd)*c(NBRCLL
$
,iXact)
ENDIF
ENDIF
enddo
ENDIF
enddo
nbrXact = nbraPlt/nbrPlt
C
Calculate the rate of resting platelets adhering to platelets on
C
the thrombus
C
uthromb (kg/s) = uthromb - kt*[Pl]*c(IC,iArThr)
uthromb = uthromb - kt*c(IC,iyPl)*BldDens*c(IC,iArThr)
$
*nbrXact*frpremain
C
Calculate the rate of active platelets adhering to platelets on
C
the thrombus
C
athromb (kg/s)= athromb - kt*[aPl]*iArThr
athromb = athromb - kt*c(IC,iyaPl)*BldDens*c(IC,iArThr)
$
*nbrXact*frpremain
ELSE
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C
C
C
C
C
C
C
C
C

In the case that we know the fraction of adhered platelets in the
cell that are active, scale the available surface area
appropriately
Calculate the rate of resting platelets adhering to platelets on
the thrombus
uthromb (kg/s) = uthromb - kt*[Pl]*c(IC,iArThr)
uthromb = uthromb - kt*c(IC,iyPl)*BldDens*c(IC,iArThr)
$
*c(IC,iXact)*frpremain
Calculate the rate of active platelets adhering to platelets on
the thrombus
athromb (kg/s)= athromb - kt*[aPl]*iArThr
athromb = athromb - kt*c(IC,iyaPl)*BldDens*c(IC,iArThr)
$
*c(IC,iXact)*frpremain
ENDIF
ENDIF

C----------------------------------------------------------------------C
Calculate the change in volumetric fraction /s of the cell occupied
C
by uthrombs and athrombs
delthu = -(uthromb+upadhm)*PltVol/cVol/PltMass/(1-xThVd)
deltha = -(athromb+apadhm)*PltVol/cVol/PltMass/(1-xThVd)
C
C
C

Calculate the fraction of adhered platelets in the cell that are
active
Xact (aPlt/Plt)
IF(abs(c(IC,iThrFr)+(deltha+delthu)*DT).LT.1E-20) THEN
c(IC,iXact) = 0
ELSE
c(IC,iXact) = (c(IC,iXact)*c(IC,iThrFr) + deltha*DT)
$
/(c(IC,iThrFr) + (deltha+delthu)*DT)
ENDIF

C

Calculate the new thrombus fraction
c(IC,iThrFr) = c(IC,iThrFr) + (deltha + delthu)*DT
IF(c(IC,iThrFr).GT.0.99) c(IC,iThrFr) = 1.0
IF(c(IC,iThrFr).LT.0.0) c(IC,iThrFr) = 0.0

C

Update the source terms
c(IC,iPlSrc) = (upadhm+uthromb)/cVol
c(IC,iaPlSrc) = (apadhm+athromb)/cVol
c(IC,iPlTadh) = -(upadhm+apadhm)/PltMass
ENDIF
enddo
enddo
endif
ENDDO

C
C
C
C

Now that the computations are complete, we focus on multi-processor
communication and assignments for new thrombus cells
Update the blood status for new thrombus cells & communicate accross
processors
itNum = 0
20
continue
itNum = itNum + 1
C
Loop through all of the cells
DO nd=1,doma_no
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if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,INTERNAL)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
C
C

Look at all cells that are thrombus
IF(c(IC,iThrFr).GT.0.99) THEN
Change blood status of cells that became thrombus
IF(c(IC,inBldSt).EQ.0.0.OR.c(IC,inBldSt).EQ.4.0) THEN
c(IC,inBldSt)=3.0
ELSE IF(c(IC,inBldSt).EQ.1.0.OR.c(IC,inBldSt).EQ.5.0) THEN
c(IC,inBldSt)=2.0
ENDIF
ENDIF
c_old(IC) = c(IC,inBldSt)
enddo
enddo
endif
ENDDO
do nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c_old(IC) = c(IC,inBldSt)
enddo
enddo
endif
enddo

c
c

If this is a parallel run, swap/assign repeatedly until the values
stop changing
if (parrun) then
needSwap = .FALSE.
do nd=1,doma_no
call arrSwap(c,nd,2,inBldSt,FLUID)
end do
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c
If the field values have changed, repeat the swap
if (c(IC,inBldSt).ne.c_old(IC).AND.itNum.lt.itMax) then
needSwap = .TRUE.
goto 21
endif
end do
end do
end do
end if
21
continue
call LGLOR(needSwap,needSwapG)
if(needSwapG) goto 20
C
Clear out c_old array
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
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call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c_old(IC) = 0
enddo
enddo
endif
ENDDO
C
C

Update viscosity,fraction active, thrombus neighbor BldSt
Loop through all of the cells
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
C
Identify thrombus cells
IF(c(IC,inBldSt).EQ.2.OR.c(IC,inBldSt).EQ.3) THEN
C***Increase the viscosity by 10%. stop at 1 poise
IF(c(IC,iviscosity).GE.0.9) THEN
c(IC,iviscosity) = 1
ELSE if(c(IC,iviscosity).LT.0.9) THEN
c(IC,iviscosity)=c(IC,iviscosity)*1.1
ENDIF
C***Increase the fraction of active platelets in thrombus cells at a
C
constant rate to achieve a fraction of one
IF(c(IC,iXact).LT.1) THEN
c(IC,iXact) = c(IC,iXact) + 1/60
ELSE
c(IC,iXact) = 1
ENDIF
C
Update blood status of neighboring cells
do nf=1,c2f(IC)%No
IS = c2f(IC)%List(nf)
C
Ignore negative (boundary) faces
IF(IS.GT.0) THEN
do nfs=1,2
IF(lfc(nfs,IS).NE.IC) THEN
NBRCLL = LFC(nfs,IS)
C
--- If the neighbor cell is fluid, change its nBldSt
IF(c(NBRCLL,inBldSt).EQ.0.0) THEN
c(NBRCLL,inBldSt) = 4.0
ELSE IF(c(NBRCLL,inBldSt).EQ.1.0) THEN
c(NBRCLL,inBldSt) = 5.0
ENDIF
c_old(NBRCLL) = c(NBRCLL,inBldSt)
ENDIF
enddo
ENDIF
enddo
C
Identify non-thrombus cells
ELSE
C***Lower the viscosity of cells where a thrombus recently embolized.
IF(c(IC,iviscosity).GE.0.07) THEN
c(IC,iviscosity) = c(IC,iviscosity)/20
ELSE IF(c(IC,iviscosity).LT.0.07) THEN
c(IC,iviscosity) = BldVisc
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ENDIF
ENDIF
enddo
enddo
endif
ENDDO
C
C

Communicate iXact accross processors
Internal cells values are accurate, record them in c_old2
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,INTERNAL)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c_old2(IC) = c(IC,iXact)
enddo
enddo
endif
ENDDO
25

C

C

itNum = 0
continue
itNum = itNum + 1
Loop through all of the cells
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,INTERNAL)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
Replace current value with correct value as recorded in c_old2
c(IC,iXact) = c_old2(IC)
c_old(IC) = c(IC,iXact)
enddo
enddo
endif
ENDDO
do nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c_old(IC) = c(IC,iXact)
enddo
enddo
endif
enddo

c
c

If this is a parallel run, swap/assign repeatedly until the values
stop changing
if (parrun) then
needSwap = .FALSE.
do nd=1,doma_no
call arrSwap(c,nd,2,iXact,FLUID)
end do
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,INTERNAL)
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do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c
If the field values have changed, repeat the swap
if (c(IC,iXact).ne.c_old(IC).AND.itNum.lt.itMax) then
needSwap = .TRUE.
goto 27
endif
end do
end do
end do
end if
27
continue
call LGLOR(needSwap,needSwapG)
if(needSwapG) goto 25
C
Clear out c_old array
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c_old(IC) = 0
c_old2(IC) = 0
enddo
enddo
endif
ENDDO
C

Organize New Thrombi
itNum = 0
30
continue
itNum = itNum + 1
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,INTERNAL)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
IF((c(IC,inBldSt).EQ.2.OR.c(IC,inBldSt).EQ.3).AND.c(IC
$
,iThrNum).LT.1.0) THEN
C
Assign Thrombus Number
C---First check for thrombus neighbors
do nf=1,c2f(IC)%No
IS = c2f(IC)%List(nf)
C
Ignore negative (boundary) faces
IF(IS.GT.0) THEN
do nfs=1,2
IF(lfc(nfs,IS).NE.IC) THEN
NBRCLL = LFC(nfs,IS)
C
--- If the neighbor cell is a thrombus, adopt its ThrNum
IF(c(NBRCLL,iThrNum).GT.0.AND.ICLMAP(NBRCLL).GT.0.AND.
$
c(IC,iThrNum).EQ.0.AND.ICLMAP(IC).GT.0)THEN
c(IC,iThrNum) = c(NBRCLL,iThrNum)
ENDIF
ENDIF
enddo
ENDIF
enddo
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C
C

C

c
c

c
c
C
C

For a new thrombus without a thrombus neighbor, assign an ID by
choosing the prostar cell number of the star index
IF(c(IC,iThrNum).EQ.0) THEN
c(IC,iThrNum) = ICLMAP(IC)
ThrLg(c(IC,iThrNum)) = .TRUE.
do row=1,NCELL
if(ThrLoc(row).EQ.0) then
ThrLoc(row) = c(IC,iThrNum)
goto 32
endif
enddo
32
continue
ThrLg(c(IC,iThrNum)) = .TRUE.
ENDIF
ENDIF
populate c_old array for comparison
c_old(IC) = c(IC,iThrNum)
enddo
enddo
endif
ENDDO
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c_old(IC) = c(IC,iThrNum)
enddo
enddo
enddo
If this is a parallel run, swap/assign repeatedly until the values
stop changing
if (parrun) then
needSwap = .FALSE.
do nd=1,doma_no
call arrSwap(c,nd,2,iThrNum,FLUID)
enddo
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
If the field values have changed, report inconsistency, and repeat
the swap
if (c(IC,iThrNum).ne.c_old(IC).AND.itNum.lt.itMax) then
needSwap = .TRUE.
If a halo cell was given a thrombus number by the swap function,
then update the ThrLgH(nT) array with a .TRUE. value
IF (c(IC,iThrNum).GT.0.AND.c_old(IC).EQ.0.AND.
$
ICLMAP(IC).LT.0)THEN
ThrLgH(c(IC,iThrNum)) = .TRUE.
ENDIF
goto 35
endif
end do
end do
end do

87

35
C

end if
continue
call LGLOR(needSwap,needSwapG)
if(needSwapG) goto 30
Clear out c_old array
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c_old(IC) = 0
enddo
enddo
endif
ENDDO

C
C

Communicate the thrombi that were created in this step and add them
to the thrombus array - ThrArray()
numZero = 0
DO row=1,NCELL
36
continue
nT = IGMAX(ThrLoc(row))
if(nT.EQ.0) then
numZero = numZero+1
else
numZero = 0
DO row1=1,GNCELL
if(ThrArray(row1).EQ.0) then
ThrArray(row1) = nT
ThrMAP(nT) = row1
IF(ThrArray(GNCELL).LT.row1) Then
ThrArray(GNCELL)=row1
EndIf
IF(ThrLoc(row).EQ.nT) ThrLoc(row) = 0
goto 36
endif
ENDDO
endif
C
Indicates 2 consecutive rows of zeroes in all ThrLoc arrays
if(numZero.EQ.2) goto 38
ENDDO
38
continue
ENDIF
C
END EXECUTION AT THE BEGINNING OF ALL TIME STEPS
C#######################################################################
ELSEIF(level.EQ.2) THEN
C#######################################################################
C
BEGIN EXECUTION AT END OF ALL TIME STEPS
C

Get the total volume of thrombus in the model
vtot = 0
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
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call cset(cs,0,nd,NSD_ALL,INTERNAL)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
IF(c(IC,inBldSt).EQ.2.OR.c(IC,inBldSt).EQ.3) THEN
vtot = vtot + VOL(IC)
ENDIF
enddo
enddo
endif
ENDDO
vtot = GSUM(vtot)
write(vThrFile,*) 'thr', TIME, vtot
C

Fill in ThrLgH array
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
IF(c(IC,iThrNum).GT.0) THEN
IF(ThrLgH(c(IC,iThrNum)).EQ..FALSE.) THEN
ThrLgH(c(IC,iThrNum)) = .TRUE.
ENDIF
ENDIF
enddo
enddo
endif
ENDDO

C

LOOP THROUGH ALL THROMBI
do row=1,ThrArray(GNCELL)
nT=ThrArray(row)
IF(nT.EQ.0) goto 40
CALL LGLOR(ThrMP(nT),ThrMPG)
shearfc = 0
height = 0
nT1 = 0
MAX = 0
MAXNBR = 0
MAXROW = 0
ncount = 0
SA1 = 0
SAthromb = 0
sheartot = 0
surfarea = 0
threshold = 0
Thrneighbor = 0
vthromb = 0
CmbThr = .FALSE.
EmbThr = .FALSE.
do row1 = 1, ThrArray(GNCELL)
ThrSA(row1) = 0.0
enddo
do row1 = 1, NeArray(NCELL)
NeArray(row1) = 0
enddo
NeArray(NCELL) = 0
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C
C
C

C

C

C

For each thrombus, determine number of cells contained, volume
of the thrombus, stress on the thrombus, and the number of cells
from each neighboring thrombus touching the reference thrombus.
IF(ThrLg(nT)) THEN
do nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,INTERNAL)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
IF(c(IC,iThrNum).EQ.nT) THEN
ncount = ncount + 1
vthromb = vthromb + VOL(IC)
do nf=1,c2f(IC)%No
IS = c2f(IC)%List(nf)
IF(IS.GT.0) THEN
do nfs=1,2
IF(lfc(nfs,IS).NE.IC) THEN
NBRCLL = LFC(nfs,IS)
If the neighbor is not a thrombus, add to SA1
if(c(NBRCLL,iThrNum).EQ.0) THEN
SA1 = SA1 + sqrt(sv(1,IS)**2+sv(2,IS)**2+sv(3,IS)
$
**2)
sheartot = sheartot + c(NBRCLL,iShrRt)*sqrt(sv(1,IS)
$
**2+sv(2,IS)**2+sv(3,IS)**2)
EndIf
If the neighbor is a thrombus, add to SAthromb and record it in ThrSA
if(abs(c(NBRCLL,iThrNum)).GT.1E-4) THEN
if(abs(c(NBRCLL,iThrNum)-c(IC,iThrNum)).GT.1E-4) THEN
SAthromb = SAthromb + sqrt(sv(1,IS)**2+sv(2,IS)**2
$
+sv(3,IS)**2)
nT1 = c(NBRCLL,iThrNum)
do row1=1,NCELL
if(ThrLoc(row1).EQ.0) then
ThrLoc(row1) = nT1
if(nT.EQ.myThromb) write(trkFile,*)
$
'ThrLoc.row = ',row1
exit
elseif(ThrLoc(row1).EQ.nT1) then
exit
endif
enddo
row1 = ThrMAP(nT1)
ThrSA(row1) = ThrSA(row1) + sqrt(sv(1,IS)**2+sv(2
$
,IS)**2+sv(3,IS)**2)
EndIf
EndIf
ENDIF
enddo
ENDIF
enddo
ENDIF
enddo
enddo
endif
enddo
Calculate the surface area
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$

do nr=0,regi_no
if(regi(nr)%type.EQ.WALL) then
call FsetBoun(fs,0,ND_ALL,NSD_ALL,nr,ISIDE_ALL)
do nset=1,fs%no
do IS=fs%ns(nset), fs%ne(nset)
IC = lfc(1,IS)
if(abs(c(IC,iThrNum)-nT).LT.1E-4) then
surfarea = surfarea + sqrt(sv(1,IS)**2+sv(2,IS)**2+sv(3
,IS)**2)
endif
enddo
enddo
endif
enddo
ENDIF

C

Create a short list of thrombi that contact the thrombus nT
numZero = 0
DO row1=1,NCELL
39
continue
nT1 = IGMAX(ThrLoc(row1))
if(nT1.EQ.0) then
numZero = numZero+1
else
numZero = 0
DO row2=1,NCELL
if(NeArray(row2).EQ.0) then
NeArray(row2) = nT1
IF(NeArray(NCELL).LT.row2) Then
NeArray(NCELL)=row2
EndIf
IF(ThrLoc(row1).EQ.nT1) ThrLoc(row1) = 0
goto 39
elseif(NeArray(row2).EQ.nT1) then
IF(ThrLoc(row1).EQ.nT1) ThrLoc(row1) = 0
goto 39
endif
ENDDO
endif
C
Indicates 2 consecutive rows of zeroes in all ThrLoc arrays
if(numZero.EQ.2) exit
ENDDO
C

IF(ThrMPG) THEN
Combine the values from all the processors
ncount = IGSUM(ncount)
vthromb = GSUM(vthromb)
SA1 = GSUM(SA1)
sheartot = GSUM(sheartot)
SAthromb = GSUM(SAthromb)
surfarea = GSUM(surfarea)
do row1=1,NeArray(NCELL)
row2=ThrMAP(NeArray(row1))
IF(nT.EQ.myThromb) then
write(trkFile,*) IHPC,'row1 = ',row1
write(trkFile,*) IHPC,'NeArray() = ',NeArray(row1)
write(trkFile,*) IHPC,'row2 = ',row2
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$

write(trkFile,*) IHPC,'ThrSA() = ',ThrSA(row2)
write(trkFile,*) IHPC,'GSUM = ',GSUM(ThrSA(row2))
ENDIF
SAsum = GSUM(ThrSA(row2))
ThrSA(row2) = SAsum
IF(nT.EQ.myThromb) write(trkFile,*) IHPC, 'ThrSA() = '
,ThrSA(row2)
enddo
ENDIF

C
C

Among the neighboring thrombi, which has more area touching
the reference thrombus?
IF(ThrLg(nT).OR.ThrLgH(nT)) THEN
IF(ThrLg(nT)) THEN
do row1=1,NeArray(NCELL)
row2 = ThrMAP(NeArray(row1))
If(MAX.LT.ThrSA(row2)) Then
MAX = ThrSA(row2)
MAXNBR = ThrArray(row2)
MAXROW = row2
Endif
enddo

C
C

If >CoalArea of thrombus surface area touches the neighbor that
has the most touching surface area, join that neighbor
IF(MAX.GT.0.0) THEN
percCA = MAX/(SAthromb+SA1+surfarea)
if(percCA.GT.CoalArea) then
Thrneighbor = MAXNBR
CmbThr = .TRUE.
endif
ENDIF
ENDIF
ENDIF
call LGLOR(CmbThr,CmbThrG)

C
C

IF(CmbThrG) THEN
ThrArray(row) = 0
ThrMAP(nT) = 0
Thrneighbor = IGMAX(Thrneighbor)
IF(ThrLg(nT).OR.ThrLgH(nT)) THEN
IF(ThrLg(nT)) THEN
ThrLg(Thrneighbor) = .TRUE.
ENDIF
IF(ThrLgH(nT)) THEN
ThrLgH(Thrneighbor) = .TRUE.
ENDIF
If the accepting thrombus is in a Halo Cell, mark it as a
Multiprocessor Thrombus
IF((ThrLg(nT).OR.ThrLg(Thrneighbor)).AND.(ThrLgH(nT).OR.
$
ThrLgH(Thrneighbor)).AND..not.ThrMP(Thrneighbor)) THEN
ThrMP(Thrneighbor) = .TRUE.
ENDIF
do nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
IF(ThrLg(nT).AND.ThrLgH(nT)) THEN
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C

C
C
C

C
C
C
C

C
C

call cset(cs,0,nd,NSD_ALL,INT_HALO)
ELSEIF(ThrLg(nT)) THEN
call cset(cs,0,nd,NSD_ALL,INTERNAL)
ELSEIF(ThrLgH(nT)) THEN
call cset(cs,0,nd,NSD_ALL,HALO)
ENDIF
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
If the cell is in the combining thrombus, change the iThrNum
IF(c(IC,iThrNum).EQ.nT) THEN
c(IC,iThrNum) = Thrneighbor
ENDIF
enddo
enddo
endif
enddo
ENDIF
ThrLg(nT) = .FALSE.
If the thrombus was combined with another thrombus, then we don't
need to run through the embolization routine for this thrombus
number.
goto 40
ENDIF
if the thrombus exists in this processor as an internal or halo cell
IF(ThrLg(nT).OR.ThrLgH(nT)) THEN
Determine threshold for embolization
-- The shearfc here is the shear force (N) over the whole thrombus
shearfc = sheartot*BldVisc
Assuming a hemisphere . . .
height = 1.5 * vthromb/surfarea
IF(height.LT.0.0001) THEN
Threshold = AdhStrs*surfarea
ELSE IF(height.GT.0.0001) THEN
Apply the criterion of Basmadjian
Threshold = AdhStrs*surfarea*(height*10000)**(-0.875)
ENDIF
Embolization Routine
IF(shearfc.GT.Threshold) THEN
EmbThr = .TRUE.
ENDIF
ENDIF
call LGLOR(EmbThr,EmbThrG)
IF(EmbThrG) THEN
ThrArray(row) = 0
ThrMAP(nT) = 0
IF(ThrLg(nT).OR.ThrLgH(nT)) THEN
IF(ThrLg(nT)) write(embFile,*) 'emb ',TIME,nT,ncount,vthromb
do nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
IF(ThrLg(nT).AND.ThrLgH(nT)) THEN
call cset(cs,0,nd,NSD_ALL,INT_HALO)
ELSEIF(ThrLg(nT)) THEN
call cset(cs,0,nd,NSD_ALL,INTERNAL)
ELSEIF(ThrLgH(nT)) THEN
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call cset(cs,0,nd,NSD_ALL,HALO)
ENDIF
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
IF(c(IC,iThrNum).EQ.nT) THEN
If the cell belongs to the thrombus being embolized
c(IC,iyPl) = 0.0
c(IC,iyaPl) = 0.0
c(IC,iThrFr) = 0.0
c(IC,iThrNum) = 0.0
c(IC,ixMact) = 0.0
c(IC,ipulse) = 0.0
c(IC,iactFr) = 0.0
c(IC,ixM) = 0.0
c(IC,inPlsFl) = 0.0
c(IC,iSp) = 1.0
c(IC,iPlSrc) = 0.0
c(IC,iaPlSrc) = 0.0
c(IC,iArThr) = 0.0

C

C

Calculate the new average thrombus volume
c(IC,iEmbVol) = (c(IC,iEmbVol)*c(IC,iNumEmb)
$
+vthromb) / (c(IC,iNumEmb) + 1)

C

Add 1 to the embolization count
c(IC,iNumEmb) = c(IC,iNumEmb) + 1

C
C

Assume cells from which thrombus has embolized become
thrombus neighbors (corrected later)
IF(c(IC,inBldSt).EQ.2.0) THEN
c(IC,inBldSt) = 5.0
ELSE IF(c(IC,inBldSt).EQ.3.0) THEN
c(IC,inBldSt) = 4.0
ENDIF
ENDIF
enddo
enddo
endif
enddo
ENDIF
Flag that embolizing thrombus no longer exists in any processor
ThrLg(nT) = .FALSE.
ThrLgH(nT) = .FALSE.
ThrMP(nT) = .FALSE.
ENDIF

C

40
C

continue
enddo
Consolidate the ThrArray() entries
Do row=1,ThrArray(GNCELL)
if(ThrArray(row).EQ.0) then
DO row1=ThrArray(GNCELL),row+1,-1
if(ThrArray(row1).NE.0) then
ThrArray(row) = ThrArray(row1)
ThrMAP(ThrArray(row)) = row
ThrArray(row1) = 0
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42
43
C

goto 42
endif
ENDDO
goto 43
endif
continue
Enddo
continue

Update the recorded last filled row in the ThrArray
intMax = ThrArray(GNCELL)
Do row=ThrArray(GNCELL),1,-1
if(ThrArray(row).EQ.0) then
intMax = row-1
else
goto 45
endif
Enddo
45
continue
ThrArray(GNCELL) = intMax

C

Check/correct thrombus-neighbor status
itNum = 0
50
continue
itNum = itNum + 1
do nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,INTERNAL)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
if(c(IC,inBldSt).EQ.4.0.OR.c(IC,inBldSt).EQ.5.0) THEN
c(IC,iArThr) = 0.0
C
Loop through all faces of the cell
do nf=1,c2f(IC)%No
IS = c2f(IC)%List(nf)
C
Ignore negative (boundary) faces
IF(IS.GT.0) THEN
do nfs=1,2
IF(lfc(nfs,IS).NE.IC) THEN
NBRCLL = LFC(nfs,IS)
C
When a neighboring cell is actually a thrombus
if(c(NBRCLL,iThrNum).GT.0) then
c(IC,iArThr) = c(IC,iArThr) + sqrt(sv(1,IS)**2+sv(2
$
,IS)**2+sv(3,IS)**2)
endif
ENDIF
enddo
ENDIF
enddo
if(c(IC,iArThr).EQ.0.0) then
IF(c(IC,inBldSt).EQ.4.0) THEN
c(IC,inBldSt) = 0.0
c(IC,iThrFr) = 0.0
ELSE IF(c(IC,inBldSt).EQ.5.0) THEN
c(IC,inBldSt) = 1.0
ENDIF
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endif
endif
c_old(IC) = c(IC,iArThr)
c_old2(IC) = c(IC,inBldSt)
enddo
enddo
endif
enddo
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c_old(IC) = c(IC,iArThr)
c_old2(IC) = c(IC,inBldSt)
enddo
enddo
enddo
c
If this is a parallel run, swap/assign repeatedly until the values
c
stop changing
if (parrun) then
needSwap = .FALSE.
do nd=1,doma_no
call arrSwap(c,nd,2,iArThr,FLUID)
call arrSwap(c,nd,2,inBldSt,FLUID)
call arrSwap(c,nd,2,iThrFr,FLUID)
end do
do nd=1,doma_no
call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c
If the field values have changed, repeat the swap
if (c(IC,iArThr).ne.c_old(IC).AND.itNum.lt.itMax) then
needSwap = .TRUE.
goto 55
endif
if (c(IC,inBldSt).ne.c_old2(IC).AND.itNum.lt.itMax) then
needSwap = .TRUE.
goto 55
endif
end do
end do
end do
end if
55
continue
call LGLOR(needSwap,needSwapG)
if(needSwapG) goto 50
C
Clear out c_old arrays
DO nd=1,doma_no
if(doma(nd)%mattyp.eq.FLUID) then
call cset(cs,0,nd,NSD_ALL,INT_HALO)
do nset=1,cs%no
do IC=cs%ns(nset),cs%ne(nset)
c_old(IC) = 0
c_old2(IC) = 0
enddo
enddo
endif
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ENDDO
C
C
c

END EXECUTION AT END OF ALL TIME STEPS
####################################################################
ENDIF
end
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